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Brystsmerter og hjertebank ved kardiologisk poliklinikk; psykologiske 
faktorer, forløp etter undersøkelsen og psykologisk behandling for plagene. 
 
Brystsmerter og hjertebank som kan være symptom på alvorlig hjertesykdom, er 
vanlige plager i befolkningen. Forløpet etter hjerteundersøkelsen for de som ikke får påvist 
hjertesykdom, er ofte dårlig. Mange fortsetter å bekymre seg for symptomene og har 
begrensninger i sine liv og nedsatt livskvalitet. Det er en utfordring å fange opp pasientene 
som trenger behandling og å utvikle gode behandlingsopplegg 
Formålet med studien var å beskrive hvor mange av pasientene henvist til kardiologisk 
poliklinikk som hadde hjertesykdom, hvor mange som hadde psykiatrisk lidelse, hvordan det 
gikk med pasientene uten hjertesykdom de kommende 6 månedene og til sist å gjøre en 
randomisert kontrollert behandlingsstudie av pasientene med vedvarende plager.  
Alle pasientene mellom 18 og 65 år som ble henvist fra allmennlege pga brystsmerter 
eller hjertebank til kardiologisk poliklinikk ved Molde sykehus og som ikke tidligere hadde 
fått diagnostisert hjertesjukdom, fikk tilbud om å delta. Av de 160 pasientene som ble 
inkludert, var det kun 4 % som fikk påvist behandlingstrengende hjertesjukdom, mens ca 40 
% av pasientene uten hjertesjukdom hadde en psykiatrisk lidelse. De vanligste var; 
panikklidelse (14%), somatiseringslidelse (14%), spesifikke fobier (20%) og depresjon (5%).  
Seks måneder etter hjerteundersøkelsen hadde 43% av pasientene med normal 
hjerteundersøkelse betydelige plager relatert til brystsmerter og hjertebank, og 70% unngikk 
fysisk aktivitet en sjelden gang eller oftere fordi de var bekymret for hjertet. Pasientene hadde 
mer depressive symptomer og var mer redd for sine kroppslige symptomer seks måneder etter 
enn før hjerteundersøkelsen. Høy score på depresjonstest forut for hjerteundersøkelsen 
predikerte dårlig prognose. Omtrent 60% av pasientene, med betydelige plager relatert til 
brystsmerter og hjertebank seks måneder etter normal hjerteundersøkelse, ønsket psykologisk 
behandling for plagene. De som ønsket behandling var mer redd for kroppslige plager og var 
mer begrenset av plagene enn andre. De trudde også i større grad før hjerteundersøkelsen at 
deres plager skyldes hjertesjukdom.  
Som en del av studien utviklet vi en behandling som besto av tre sesjoner med 
kognitiv terapi der eksponering for fysisk aktivitet var et av elementene. Behandlingen ble 
prøvd ut i en randomisert kontrollert studie (RCT) til 40 pasienter med oppfølgingstid på ett år 
etter avsluttet behandling. Behandlingen hadde positiv effekt på frykt for kroppslige 
symptomer, på depressive symptomer, unngåelse av fysisk aktivitet og flere områder av 
helserelatert livskvalitet. Endringen i frykt for kroppslige symptomer syntes å være en viktig 
faktor for hele behandlingseffekten.   
Konklusjon: Få av pasientene med brystsmerter og hjertebank som henvises elektivt til 
kardiologisk poliklinikk har hjertesykdom, mange av pasientene uten hjertesykdom har 
vedvarende plager med funksjonsreduksjon i månedene etter hjerteundersøkelsen. Mange av 
disse har effekt av tre timer med kognitiv terapi der eksponering for fysisk belastning på 
ergometersykkel er inkludert. 
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Chest pain and palpitations in a cardiac setting; psychological 
factors, outcome and treatment 
 
 
General introduction 
In internal medicine the main focus is identification and treatment of well defined 
physical illnesses. In psychosomatic medicine a bio-psycho-social focus is more common. 
The reason for attending the health care system might be complex, and physical illness might 
play a minor role or not be present at all. One of the fields in internal medicine, where 
psychological factors are important, is cardiology. The experience of cardiac complaints may 
range from living with a severe cardiac disorder to the fear of having this, even when no 
somatic disorder may be detected. Chest pain and palpitations are the two most common 
complaints which are associated with heart disorder. Since chest pain and palpitations 
potentially are symptoms of serious cardiac disorders, a main focus for cardiologists is to 
evaluate whether there is a cardiac condition present that may explain the symptoms. When a 
cardiac diagnosis, such as myocardial infarction, angina pectoris or arrhythmias, is made, the 
treatment is often standardized and well documented. However, in cardiac as well as in 
primary health care settings a high proportion of patients who present chest pain or 
palpitations as main symptoms do not have any heart disease or other medical disorders. 
(Mayou, Bryant, Forfar & Clark 1994; Weber & Kapoor 1996; Dammen, Arnesen, Ekeberg et 
al. 1999, Kroenke & Mangelsdorff 1989). Non-cardiac chest pain and benign palpitations are 
diagnoses of exclusion, defined as respectively, recurrent episodes of retrosternal 
pain/discomfort or unpleasant sensations of heartbeat in the absence of cardiac disease. These 
conditions are poorly understood and routines for treatments are lacking (Bass & Mayou 
2002; Mayou 1998).  
The main focus of this thesis was to a) estimate the prevalence of cardiac and 
psychiatric diagnoses of patients who were referred to cardiac outpatient evaluation with chest 
pain or palpitations, b) evaluate the six-month outcome, predictors of poor outcome, and the 
interest in psychological treatment among those where no cardiac condition was detected and 
c) develop a treatment manual for patients with non-cardiac chest pain or benign palpitations 
and evaluate the effect of the treatment  by conducting a randomized controlled trial.  
 
 
1.1.1. Epidemiology 
In population-based studies the lifetime-prevalence of chest pain has been estimated to 
vary between 20-39% (Eslick, Jones & Talley 2003; Wong, Lam, Cheng et al. 2004), while 
11% reported that palpitations had a significant influence on their subjective well being (Rief, 
Hessel & Braehler 2001). Palpitations and chest pain are among the most common symptoms 
in primary care settings (Kroenke, Arrington & Mangelsdorff 1990), and the two most 
common reasons for referral to cardiologist (Mayou 1998).  
 
  
1.1.2. Aetiology of chest pain or palpitations  
Various conditions may be associated with chest pain. In one review Eslick (2004) 
reported the prevalence of the following conditions: ischemic heart disease 7-31%, 
gastrointestinal reflux 9-88%, psychiatric disorders 1-79% and musculoskeletal disorders 11-
23%. The large ranges in prevalence rates may to some extent be explained by different 
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populations being investigated (population-based, hospital-based and out-patient based) and 
differences in assessment methods. 
 In a study addressing the aetiology of palpitations, Mayou et al. (Mayou, Sprigings, 
Birkhead & Price 2003) found that palpitations were associated with detected or probable 
arrhythmias in 34% of the patients, detected or probable extra systoles in 41%, and awareness 
of sinus rhythm and no detection of arrhythmias in 26%. Barsky et al. (Barsky, Delamater 
Clancy et al. 1996) and Weber et al. (1996) found almost similar prevalence of cardiac 
etiology among patients referred for palpitations by reporting prevalence of  clinically 
significant arrhythmias as 34% and prevalence of cardiac etiology of the palpitations as 43%, 
respectively.   
The reasons for development and maintenance of non-cardiac chest pain or benign 
palpitations are not well understood. Gastroesophageal reflux, oesophageal dysmotility, 
musculoskeletal disorders, panic disorder (PD) and benign arrhythmias are assumed to be the 
cause in some patients. Often, however, multiple factors may explain the symptoms. Mayou 
has proposed a multifactorial model for the development and maintenance of non-cardiac 
chest pain and benign palpitations. A central component is the attribution or cognitive 
appraisal, whereby physiological or minor pathological symptoms are misinterpreted as 
evidence of serious illness. A hypochondriacal tendency, psychiatric disorders, inappropriate 
illness beliefs and previous experience of illness may all predispose to misinterpretation of 
symptoms. The most important maintaining factors are the persistence of bodily 
misperception, anxiety or other psychiatric disorders, and a continuing belief that the 
symptoms are caused by a serious physical disorder (Mayou 1998).  
 
 
1.1.3. Health-related quality of life  
The Short Form 36 (SF-36) has been developed for the assessment of health-related 
quality of life (HRQOL). It measures the patients’ own perception of psychological and 
physical distress and functional ability, and is suitable for use both in physical and psychiatric 
disorders. This makes it useful in fields like cardiology (Schenkeveld, Pedersen, van Nierop et 
al. 2010), where the potential consequences of physical disorders are huge and consequently 
the mental perspective is important. Since the instrument measures both psychological and 
physical consequences of a disorder, it gives the opportunity to compare the disability of 
similar diagnoses in different settings. Dammen et al. (Dammen, Ekeberg, Arnesen & Friis 
2008) evaluated 66 non-cardiac patients with PD in a cardiac outpatient clinic and found that 
these were as impaired as PD patients in psychiatric settings regarding HRQOL. Moreover, in 
a recent review Eslick (Eslick 2008) reported that HRQOL was substantially lower among 
patients with non-cardiac chest pain compared to the general population. To our knowledge no 
previous study has explored HRQOL (SF-36) in patients with palpitations. 
 
 
 
Introduction to paper I 
1.2.0. Prevalence of cardiac and psychiatric diagnoses among patients with chest pain or 
palpitations  
Symptoms associated with cardiac disorders are often unspecific and their origin is 
difficult to detect without extensive evaluation. As a consequence more than 50% of patients 
visiting cardiac units with chest pain or palpitations do not have any cardiac disorder 
(Dammen et al. 1999; Mayou et al. 1994; Bass & Mayou 2002). 
Previous studies in cardiac settings have reported that non-cardiac chest pain and 
benign palpitations are associated with psychiatric disorders (Dammen et al. 1999; Ehlers, 
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Mayou, Sprigings & Birkhead 2000; Barsky, Cleary, Coeytaux & Ruskin 1994). The most 
commonly reported psychiatric disorder is panic disorder (PD), and both chest pain and 
palpitations are common symptom during panic attacks (Table 1). However, probably because 
of the focus on the physical symptoms, these patients seldom receive psychiatric diagnoses 
and adequate treatment. One study in a cardiac setting reported that only in 3 out of 76 PD 
patients were identified and given adequate treatment prior to referral (Dammen et al. 1999). 
This is in line with a study where only 2% of the patients with PD were recognized as 
suffering from PD when attending emergency department cardiologists (Fleet, Dupuis, 
Marchand et al. 1996). In addition to PD the prevalences of generalized anxiety disorder 
(GAD), specific phobias, somatisation disorder and depression have also been reported to be 
high among patients referred for chest pain, compared to the general population (Dammen et 
al. 1999; Fleet, Dupuis, Marchant et al. 1998; White, Raffa, Jakle et al. 2008).  
During the past decade there has been a change in hospitalization policy for patients 
with acute coronary syndrome. Most patients with new onset angina are now urgently 
hospitalized and not referred for outpatient evaluation. This change might have influenced the 
prevalence of cardiac as well as psychiatric disorders in the outpatient clinics. A recent study 
(White et al. 2008) investigated 147 patients with non-cardiac chest pain seeking evaluation at 
a cardiological centre. The prevalence of any anxiety disorder was 41%, and the prevalences 
of the specific disorders were PD 12%, social phobia 16%, GAD 13%, specific phobias 14%, 
and depression 8%. The prevalence rate of PD differs from previous studies, in which the 
rates have been reported to be at least 25% in various cardiac settings (Dammen et al. 1999; 
Fleet et al. 1998). This tendency might reflect the changes in referral policy. Since panic 
attacks in most patients present with acute and dramatic symptoms, it is likely that more 
patients with panic disorder are sent to the emergency units. 
Less is known about the prevalence of psychiatric disorders among patients with 
benign palpitations, but studies conducted before change in hospitalization policy have 
estimated the prevalence of panic disorder to 14-23% (Barsky et al. 1994; Ehlers et al. 2000). 
 
 
1.2.1. Substance abuse or dependence  
One review reported the prevalence of additional alcohol and/or substance abuse or 
dependence to be about 20 % among patients with panic disorder (Sansone, Griffith & 
Sansone 2005). Dammen et al. (1999) reported a prevalence of 5% of alcohol/drug abuse in 
patients with PD referred to a cardiac outpatient clinic for chest pain. This may indicate that 
alcohol/drug abuse is a smaller problem among patients referred to cardiological units 
compared to patients with PD in general, but this subject is sparsely investigated.  
 
 
 
Introduction to paper II 
1.3.0. Follow-up studies 
Follow-up studies of patients with non-cardiac chest pain or benign palpitations show 
discouraging results; maintenance of symptoms that affect daily living, worrying about the 
heart, reduced HRQOL, and increased use of health care services are common. Potts et al. 
(Potts & Bass 1995) investigated patients with normal (n=31) or near to normal coronary 
arteries (n=15) eleven years after coronary angiography. At follow up 74% reported 
continuous chest pain, 39% experienced this at least once a week. Outcome of chest pain was 
associated with reduced functional capacity as measured by Global Assessment of Function 
Scale (GAF). Anxiety disorders were common, with panic disorder (15%) as the most 
prevalent diagnosis. Bringager et al. (Bringager, Friis, Arnesen & Dammen 2008) carried out 
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a nine- year follow-up study of patients with non-cardiac chest pain (n=150) diagnosed at an 
outpatient cardiac unit. Of the 55 patients with PD at baseline, 14 (25%) still met the criteria 
for PD during the month before the interview. The patients with PD at baseline had 
significantly higher levels of self-reported depression, somatization, anxiety cognitions and 
hypochondriac concerns at follow-up, as well as generally low HRQOL. In a study by Mayou 
et al. (Mayou, Sprigings & Gilbert 1999), 81 patients referred for palpitations were evaluated 
at the time of ECG-monitoring and 18 months later. Forty-six had a normal heart (no 
arrhythmias or other cardiac disorders detected by 24-hour ECG). Limitations in everyday life 
were substantial. Only a minority reported improvement at follow-up, and there were few 
differences between those with normal and abnormal heart (cardiologically significant 
arrhythmias, cardiac enlargement, or cardiomyopathy). Furthermore, Mayou et al. (1994) 
investigated patients with non-cardiac chest pain (n=33) or benign palpitations (n=18) six 
months and three years after the cardiac evaluation. A substantial proportion reported 
continuing symptoms, emotional stress, limitations in everyday activities, and concern about 
the heart.  
In these previous follow-up studies some interesting information is lacking: Does fear 
of bodily symptoms change following a normal heart test (pre cardiac evaluation compared to 
six-month after). Will patients avoid physical and other activities because of worry about 
cardiac illness, despite negative tests? Do fear of bodily symptoms and symptoms of 
depression at attendance predict outcome? Will the outcome in terms of HRQOL differ 
between those with non-cardiac chest pain and those with benign palpitations?  
 
 
1.3.1. Non-cardiac chest pain vs benign palpitations 
Comparison of psychological factors in non-cardiac chest pain and benign palpitations 
Limited empirical evidence supports the common assumption that patients with non-
cardiac chest pain and benign palpitations have similar psychological characteristics and may 
be regarded as one group. The assessment of the similarities and differences between patients 
with these complaints may be important both for the understanding of the complaints and for 
the development of intervention strategies. The only previous study comparing these two 
groups (Mayou et al. 1994) found no significant differences in mental distress or prevalence 
of psychiatric disorders between patients with non-cardiac chest pain (N = 33) and benign 
palpitations (N = 18). However, patients with palpitations were more likely to be women, 
younger, report previous psychiatric problems, and have less social disability at the six-month 
follow-up. This study did not evaluate the degree of fear of the bodily sensations or the 
HRQOL. 
 
 
1.3.2. Prediction of poor outcome 
Prediction of poor outcome in terms of symptom maintenance, impact of the symptoms, and 
avoidance of physical activity 
It is not stated whether patients should be screened for poor outcome at the cardiac 
evaluation, or if it is more appropriate to have a system which later identifies those with no 
cardiac disease and persistent complaints. Mayou and colleagues (Mayou, Bass & Bryant 
1999) proposed a stepped care approach. This approach includes: 1) reassurance of the 
negative results of the cardiological investigation; 2) a six week follow-up to repeat 
reassurance and to address persisting pain and distress, give alternative explanations to chest 
pain e.g. musculoskeletal or esophagal problems; 3) a three to six months follow-up to 
confirm improvement for those with only mild symptoms at the first follow-up; 4) regular 
follow-up appointments for those with persistent chest pain who are highly distressed and 
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experience severe disability. For some patients a psychological intervention (cognitive 
behavioral therapy) or antidepressive treatment may be indicated.  
Dammen et al. (Dammen, Ekeberg, Arnesen & Friis 1999) and Fleet et al. (Fleet & 
Beitman 1997) have developed models to detect PD in cardiac settings. However, previous 
studies have reported that patients with non-cardiac chest pain, even when psychiatric 
disorders are detected during the evaluation, are rarely given any specific treatment for such 
disorders in addition to the cardiac evaluation (Fleet et al. 1996).  
As far as we know, none has focused on screening instruments for predicting 
persistent complaints among these patients. For patients with low back pain a resent review 
(Chou & Shekelle 2010) has evaluated predictors of persistent disabling low back pain. They 
reported that maladaptive pain coping behavior including fear avoidance (avoidance of work, 
movement or other activities due to fear that they will damage or worsening the back) and 
catastophizing (pain coping characterized by excessively negative thoughts and statements 
about the future), was predictor of persistent disabling low back pain through one year.  
If it is possible to find an appropriate instrument to detect patients at the cardiac 
evaluation with poor outcome in terms of symptom maintenance, it would be easier to offer 
these patients adequate treatment. Therefore we wanted to study the screening properties of 
different variables and to test whether these might be useful as screening instruments. 
 
 
 
1.3.3. Symptom attribution  
Doubts have been raised whether patients with non-cardiac chest pain or benign 
palpitations, who are referred to cardiac or other medical units, will accept non-physical 
explanations of their complaints, and attend effective psychological treatment if available. 
Dammen et al. found that patients with PD, compared to those without PD, were more likely 
to believe that their chest pain was caused by heart disease (Dammen et al. 1999). Patients 
without coronary artery disease (CAD) in general rated it as more likely that their chest pain 
was caused by psychological distress than CAD (Dammen, Arnesen, Ekeberg & Friis 2004). 
However, neither the patients nor the cardiologists were convinced about the cause before 
investigation (general cardiac evaluation and bicycle stress test) was performed. The 
acceptance of psychological treatment for these patients might be associated with their 
symptom attribution and fear of the symptoms.   
 
 
1.3.4. Interest in psychological treatment 
Among patients with non-cardiac chest pain, only 40–60% have wanted to enter 
treatment studies, despite the proven effect of cognitive behavioral therapy (CBT) (Kisely, 
Campbell, Skerritt, & Yelland 2010). One study (Van Peski Oosterbaan, Spinhoven, Van der 
Does et al. 1998) found that patients, who were interested in psychological treatment, were 
more likely to be men, younger, had more limitations in activities and a non-significant 
tendency to higher frequency of chest pain. They did not differ from patients who did not 
want treatment regarding duration of complaints or intensity of pain. This study did not 
evaluate the presence of psychiatric disorders or whether the patients actually were willing to 
receive psychological treatment. To our knowledge, no previous study has assessed the 
characteristics of patients who accept psychological treatment for benign palpitations.  
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1.3.5. The psychological consequences of undergoing normal cardiologic investigation   
The general attitude is that there should be a low threshold for cardiac investigation. 
The main reason for this is the need to detect and treat cardiac disorders as early as possible. It 
has been generally accepted that information about the test results is sufficient to reassure the 
patients with normal tests that they do not have a medical problem, however, this assumption 
is not empirically supported (Bass & Mayou 2002; Potts & Bass 1995). McDonald et al. 
(McDonald, Daly, Jelinek et al. 1996) have evaluated the effects of reassurance by normal test 
results one year after the tests. The data were collected during interviews lasting about two 
hours. All patients who presented with symptoms of palpitations or chest pain (n=10,) were 
left with anxiety about the heart, despite normal test results and reassurance from cardiologist. 
Of 28 patients who were referred because of a murmur (no symptoms), 20 became anxious 
after the detection of the murmur and of these 11 had heart related anxiety at follow-up. The 
residual anxiety was related to the lack of adequate patient understanding that murmur and 
symptoms could persist even though the heart was normal. The reduction of anxiety was 
directly related to improvement of this understanding. 
In the present study we wanted to evaluate the fear of bodily symptoms before cardiac 
evaluation and at six-month follow-up. By comparing the intensity of such fear at baseline 
and follow-up, we would get an indication about whether the cardiac evaluation led to change 
in fear of bodily symptoms. Since catastrophic misinterpretations of bodily sensations are 
supposed to be crucial elements in the aetiology of symptom maintenance, it is important to 
evaluate the effect of the cardiac investigation on the interpretation of the symptoms.  
 
 
 
 
Introduction to paper III 
1.4.0. Treatment of non-cardiac chest pain or benign palpitations  
In a recent Cochrane review Kisely et al. (2010) evaluated the effectiveness of 
psychological interventions for non-cardiac chest pain on the basis of ten randomized 
controlled trials (RCT). The review included different types of interventions; five studies on  
individual CBT (Mayou, Bryant, Sanders et al. 1997; Esler, Barlow, Woolard et al. 2003; 
Sanders, Bass, Mayou et al. 1997; Klimes, Mayou, Pearce et al. 1990; Van Peski-Oosterbaan, 
Spinhoven, van Rood et al. 1999), one study of group CBT (Potts, Lewin, Fox & Johnstone 
1999), one study of hyperventilation control training (De Guire, Gevirtz, Hawkinson & Dixon 
1996), one of hypnotherapy (Jones, Cooper, Miller et al. 2006), one of autogenic training 
(Asbury, Kanji, Ernst et al. 2009) and one study (Tyni-Lenne, Stryjan, Eriksson et al. 2002) 
focussed on relaxation and physical exercise (cycle ergometer; 30 minutes three times a week 
for eight weeks). Two studies (Potts et al. 1999; Klimes et al. 1990) had  waiting list control 
groups, where the control patients received s delayed treatment, in one study (Jones et al. 
2006)  the control group received supportive listening plus placebo medication, otherwise the 
interventions were compared with treatment as usual/no treatment. The CBT-interventions 
ranged from one to twelve sessions. The study of hypnotherapy used 12 sessions during 17 
weeks with no follow-up measurements (Jones et al. 2006). The review concluded that CBT 
and hypnotherapy probably were effective in the short term, otherwise the effects of treatment 
were less clear. CBT interventions with more than one session seemed to have better 
outcome, especially for more generalised disability. It could not, however, be determined how 
many sessions were necessary, or what the most important elements in the therapy were. No 
CBT study had explicitly investigated avoidance of physical activity because of worry about 
the heart, or included exposure to physical activity in the treatment. The authors called for 
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new RCT-studies with adequate outcome measures, explicitly described manualized 
interventions, and at least 12 months follow-up.  
Two recent RCT studies, both reporting some effects of the interventions, were not 
included in the review; one comprised 18 Johrei sessions (energy healing) (Gasiorowska, 
Navarro-Rodriquez, Dickman et al. 2008) and one studied 11 sessions of functional relaxation 
and patient education (Lahmann, Loew, Tritt & Nickel 2008). None of these two studies had 
follow-up measurements. Eighteen sessions of Johrei had significant effect on symptom 
intensity, but not on any of the eight domains of SF-36. Eleven sessions of functional 
relaxation and patient education was effective on mean score and two subscales (somatisation 
and anxiety) of SCL-90, and on cardiovascular complaints of Giesssen Inventory of 
Complaints.  
 Some RCT studies have reported beneficial effect of antidepressant medication in 
patients with non-cardiac chest pain. Imipramine reduced chest pain (Cannon, Quyyumi, 
Mincemoyer et al. 1994; Cox, Hann & Kaski 1998) and sertraline (Varia, Logue, O’Connor et 
al. 2000) also had effect on one of eight domains of HRQOL (SF-36). A recent RCT study 
compared CBT (individual, 6-12 sessions of 45-60 minutes) with sertraline (Spinhoven, Van 
der Does, Van Dijk & Van Rood 2010). CBT was superior to sertraline in reducing chest pain 
(combination score from frequency, duration and intensity), but the interventions did not 
differ significantly regarding change in scores of heart focus anxiety. The follow-up time in 
these studies was less than three months. 
For treatment of benign palpitations only one RCT-study has been published (Mayou, 
Sprigings, Birkhead & Price 2002). In this study the intervention was based on cognitive 
behavioural principles, delivered by a cardiac nurse, and varied from one telephone call up to 
three out-patient visits and telephone calls. At three-month follow-up the there were 
statistically significant benefits for intervention group as 78% vs 43% in the control group, 
were classified to have good or excellent activity level.  Regarding quality of life, assessed by 
the Dartmouth Co-op Scale, there was significantly larger improvement in one (physical 
fitness) of ten subscales. 
A recent review (Quartana, Campbell & Edwards 2009) evaluated the different aspects 
of pain catastrophizing. The study offered evidence to suggest that pain catastrophizing 
represents an important process factor in pain treatment. Smeets et al. (Smeets, Vlaeyen, 
Kester & Knottnerus 2006) reported that CBT as well as physical exercise (aerobic, strength 
and endurance training) were associated with changes in pain catastrophizing, which seemed 
to mediate the outcome of the treatments among patients with chronic low back pain. 
Furthermore, in a review about the effect of physical activity on anxiety, Martinsen 
(Martinsen 2008) stated that physical activity will help patients to normalize their catastrophic 
interpretation of bodily symptoms. 
Patients with non-cardiac chest pain and benign palpitations may have high levels of 
fear of bodily sensations, and it is assumed that a reduction of this fear will lead to decrease in 
the patient limitations (Mayou 1998). We therefore assumed that exposure to physical activity, 
as a part of CBT, would be a useful element, and it was therefore included in the treatment 
manual.  
Since non-cardiac chest pain and benign palpitations have a tendency to poor long 
term outcome it is important to evaluate the long term effects of treatment. Most previous 
studies have short follow-ups, and none of the trials using CBT has as long as 12 months 
follow-up after the end of intervention. Thus, we wanted to conduct a 12 month follow-up 
study. 
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1.4.1. Mediator of change 
Change in interpretations of symptoms as mediator for depression and avoidance of physical 
activity  
The main goal for RCT studies is to compare the effects of treatments. Process 
research is dealing with how a given intervention works. One way to investigate how the 
intervention works is to measure the association between central elements in the treatment 
(e.g. symptom perception) and other outcome measures. When analysing the results of a 
RCT-trial , van Peski-Oosterbaan et al. (Van Peski-Oosterbaan, Spinhoven, Van der Does et 
al. 1999) found a significant association between interpretation of chest symptoms and chest 
pain reduction. They did not find similar association for fear of bodily sensations (BSQ) and 
chest pain reduction. No previous study has analysed whether reductions in BSQ may mediate 
changes in more general measures like avoidance of physical activity or BDI.   
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Aims of the study 
 
Paper I 
 
2.1. To estimate the prevalence of cardiac and psychiatric diagnoses among consecutive 
patients referred to cardiac outpatient evaluation for chest pain or palpitations.  
 
 
 
Paper II  
 
2.2. Describe the clinical status prior to cardiac evaluation and at six-month follow-up for 
patients with non-cardiac chest pain or benign palpitations 
 
2.3. Compare the demographic and psychological characteristics of patients with non-cardiac 
chest pain and benign palpitations  
 
2.4. Identify factors that predict poor outcome and evaluate their suitability for screening  
 
2.5. Identify factors associated with the patient’s interest in psychological treatment 
 
 
 
Paper III 
 
2.6. Evaluate the effect of short-term cognitive behavioral therapy for patients with non-
cardiac chest pain or benign palpitations with 12 months follow-up 
 
2.7. Evaluate whether changes in depression and avoidance of physical activity were mediated 
by a reduction in fear of bodily sensations.   
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Material and methods 
3.1.0. Definitions 
In this study we have defined non-cardiac chest pain as chest pain where no relevant 
heart disorder is detected after a proper evaluation (bicycle stress test, and if needed 
myocardial scintigraphy, and/or coronary angiography), and benign palpitations as a physical 
sensation of irregularities in the beating of the heart, without detection of serous arrhythmias 
after a proper evaluation (12-lead resting electrocardiogram (ECG) and Holter monitoring and 
in addition seven days of ECG monitoring (R-test) when appropriate). 
 
 
3.1.1. Patients in paper I and II 
At attendance 
Consecutive patients aged between 18 and 65, who were referred to the cardiac 
outpatient unit at Molde Hospital, Norway, for evaluation of chest pain or palpitations 
between May 2006 and May 2007 were asked to participate. The outpatient clinic receives all 
referrals in a catchment area of about 75 000 inhabitants. 
The head of the cardiac unit screened all referrals. The inclusion criteria were: (1) referral for 
chest pain or arrhythmias, (2) age 18–65 years, and (3) the ability to understand and write 
Norwegian. The exclusion criteria were: (1) mental retardation, (2) psychosis, and (3) 
previous organic heart disease confirmed by a cardiologist. Of 219 consecutive patients, 21 
cancelled both the cardiological and the psychiatric evaluation, 36 did not want to participate 
in the study, and two were excluded (one did not speak Norwegian properly and one was 
mentally retarded). A total of 160/198 patients (81%) completed the study at attendance. Of 
these, 112 were referred for chest pain and 48 for palpitations. The 36 who did not want to 
participate in the study did not differ significantly from the participants regarding age, sex, 
prevalence of CHD (result of the cardiac evaluation), or chest pain/palpitations ratio. 
All included patients signed an informed consent form. The recruitment of subjects at 
attendance is summarized in Figure 1. 
Among the 160 patients who participated in psychiatric and cardiac evaluations at 
attendance, six had coronary heart disease confirmed by the cardiac evaluation (five referred 
for chest pain and one for palpitations). No arrhythmias in need of treatment were detected. 
The non-cardiac sample at attendance consisted of 154 patients, 107 patients were 
referred because of chest pain and 47 for palpitations.  
 
Asked
to
participate
N=219
Participated in the study
Chest pain N=112, Palpiatations N=48
Total N=160
Cancelled N=21
Excluded N=2
Did not want
Chest pain N=27, Palpitations N=9  
Total N=36
 
 
 
Figure 1 Recruitment of subjects in the study  
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Sample at six-month follow-up 
Of the total sample of 154 patients with non-cardiac chest pain or benign palpitations 
at attendance, 138 (90%) responded to mailed questionnaires at the six-month follow-up: 95 
(89%) in the chest pain group and 43 (91%) in the palpitations group. Those who did not 
respond at follow-up did not differ from the participants regarding gender, age, prevalence of 
psychiatric disorders, or scores on any variable with importance for outcome (i.e., depression, 
anxiety symptoms, and avoidance) at baseline. 
 
 
 
3.1.2. Procedure 
The cardiologic outpatient unit sent letters with time for evaluation to patients who 
were routinely referred for cardiac investigation. In the same letters the patients got 
information about the study. The patients were informed that the purpose of the study was to 
evaluate psychological distress and prevalence of psychiatric disorders among patients 
referred for chest pain or palpitations. The psychiatric evaluation and assessments at 
attendance were performed before the cardiac evaluation; thus, both the interviewer and the 
patients were blind to the results of the cardiac evaluation. All information about the patients 
at the six-month follow-up was collected by mail (except for interest in treatment, for which 
some patients were phoned). 
 
 
3.1.3. Evaluation and assessments 
Sex, age, marital status (married/cohabiting, yes or no), education (vocational 
school/university, yes or no), work status (main source of income past 6 months; work, 
sickness benefit, other), duration of symptoms, and number of days on sick leave during the 
three months prior to consultation were registered at attendance. 
 
 
Cardiac evaluation 
In addition to routine cardiac evaluation, the cardiologist completed a form consisting 
of risk factors for CHD (smoking habits and blood pressure) and clinical descriptors for chest 
pain (duration, character, site and radiation of chest pain, and precipitating factors) or 
palpitations (duration of symptoms, character of arrhythmias or complaints, and syncope). All 
patients underwent a 12-lead resting electrocardiogram (ECG). Blood samples were taken to 
analyse fasting blood sugar, CRP, total cholesterol, fT4, and TSH.  
The interpretation of the standard bicycle stress test was based on ST-segment deviation, 
arrhythmias, blood pressure response, and the presence of chest pain. The evaluation was 
based on the patient’s history, ECG, and the results of the stress test. If the cardiologist found 
the results consistent with CHD, or if there was doubt about this, the patients were referred for 
myocardial scintigraphy, or coronary angiography.  
If there was doubt about the conclusion from the Holter monitoring, the patients also 
underwent seven days of ECG monitoring (R-test) or a bicycle stress test. A flow diagram 
shows the participation in the different cardiac investigations (Figure 2). 
 
The cardiac evaluations were performed and administered at the Cardiology unit at 
Molde Hospital, except for the coronary angiography, which was performed at St. Olav 
University Hospital, Trondheim. 
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Referred for
chest pain
N=112
Referred for
palpitations   
N=48
Exercise
ECG
N=117
N=112
N=1
Holter
N=47
N=47
N=4
Myocardial
scintigraphy
N=16
7-days
ECG
N=5
Coronary
angiography
N=10
N=8
N=5
N=2
N=16
Coronary
heart disease
N=6
Non cardiac
chest pain /
Benign 
palpitations
N=154
N=38
N=93
N=6
N=14
N=4
N=5
 
 
 
Cardiac investigators 
Three cardiologists and three physicians under supervision by the cardiologist 
performed the cardiac evaluations. The cardiologists and the physicians were employed at the 
unit where the study took place.  
 
 
Psychiatric evaluation 
Psychiatric disorders were assessed using the Structured Clinical Interview for DSM-
IV axis I disorders, (SCID-I). The interviews were performed by the first author, who is an 
experienced psychiatrist, who was trained in the use of the instrument. For current diagnoses, 
the criteria had to be met within one month prior to the interview; for lifetime diagnoses, the 
criteria had to be met previously or currently. 
 
 
Fear of bodily sensations, depression, and health related quality of life 
The Body Sensations Questionnaire (BSQ) (Chambless, Caputo, Bright & Gallagher 
1984) measures fear of body sensations. It consists of 17 different bodily symptoms rated on a 
1-5 scale. The questionnaire was noted to be highly internally consistent (Cronbach alpha 
=0.87). The stability over a period of 31 days was moderately good (r=0.67), and the change 
with treatment was highly significant. BSQ relations with other indices of relevant 
psychopathology were also satisfactory (Chambless et al 1984). It is previously used in 
studies of patients with non-cardiac chest pain and benign palpitations (Dammen et al. 1999; 
Ehlers et al. 2000).  
 
The Beck Depression Inventory (BDI) (Beck & Steer 1993) measures the level of 
depression. It consists of 21 items rated on a 0-3 scale, and sum score ranges from 0-63.  
 
The Mobility Inventory (MI) (Chambless, Caputo, Jasin et al. 1985) measures 
avoidance in 24 different places or situations, and is scored on a 1-5 scale. For each place or 
situation, the patients score for being alone or accompanied by others. 
 
The 36-item SF-36 (Ware & Sherbourne 1992) measures patient perceptions of 
HRQOL and their functioning across eight areas of life (domains): physical functioning, 
physical role limitations (i.e., role limitations because of physical health problems), bodily 
Figure 2 Cardiac evaluation  
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pain, general health perception, vitality, social functioning, emotional role limitations (i.e., 
role limitations because of emotional problems), and mental health. Domain scores range 
from 0 to 100; higher scores indicate better health. A validated Norwegian translation of the 
SF-36 was used in the present study (Loge, Kaasa, Hjermstad & kvien 1998; Loge & Kaasa 
1998).  
 
All instruments (BSQ, BDI, MI, and SF-36) have sound psychometric properties and 
are widely used clinically and in research. 
 
 
Symptom attribution 
Patients were asked the following questions: (1) Do you think your symptoms are 
caused by a heart disease?; and (2) Do you think your symptoms are caused by mental stress 
or anxiety? The choices of response were: 1. not likely; 2. less likely; 3. most likely; 4. for 
sure. 
 
 
Treatment of psychiatric disorders 
Psychotherapy was defined as at least one session with psychological 
treatment/counselling for mental problems during lifetime. The use of the following current 
medications was registered: antidepressants, anxiolytics, hypnotics, or other psychotropic 
drugs. 
 
 
Frequency of symptoms 
Symptoms of chest pain or palpitations were recorded on a registration form, 
developed for the present study. The frequency of symptoms was rated as 1 “daily”, 2 
“weekly or more often”, 3 “rare but sometimes”, or 4 “no symptoms in the last 6 months”. For 
patients who reported both chest pain and palpitations, the highest frequency score was 
entered in the statistical analyses. 
 
 
Consequences of chest pain and palpitation 
The impact of cardiac symptoms on the domains of family, social, and work life were 
recorded separately as “very much”, “quite much”, “some”, and “no”, and the highest score 
(the domain mostly affected) was used. 
Avoidance of physical activity was assessed using the following question: “Do you avoid 
physical activity because of worries about the heart?”. The response categories were “often”, 
“now and then”, “rare but sometimes”, and “never”. 
 
 
Clinically significant complaints at follow-up 
Clinically significant complaints at follow-up were defined as reports of at least one of 
the following: At least weekly symptoms; at least moderate impact on family life, social life, 
or work; or avoiding physical activity now and then because of worries about the heart. 
Clinically significant complaints were categorized as present or not present. The purpose of 
the generation of this variable was to identify individuals who were considered to have poor 
outcome at six-month follow-up. All patients with clinically significant complaints were 
evaluated as having poor outcome. 
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Interest in psychological treatment 
At the six-month follow-up, all patients were asked the following question: “Do you 
want to participate in a research project, in which we aim to explore the efficacy of a 
treatment regimen developed to increase coping ability regarding chest pain and/or 
palpitations”. Response categories were: 1) “yes”; 2) “phone me for more information”; and 
3) “no”. Of all participants at follow-up 44 patients were interested in psychological 
treatment, and of these, 11 received information by telephone before making a decision.  
 
Among those who fulfilled the criteria for clinically significant complaints (N=60), 36 
(60%) were interested in psychological treatment. When we compared patients who were 
interested in psychological treatment with patients who were not interested, only patients with 
clinically significant complaints (N=60) were included in the analyses. In this way only 
patients who we evaluated as having poor outcome, were compared. 
 
 
 
Randomized controlled trial 
3.2.0. Patients 
At six-month follow-up patients were invited to take part in a treatment study. Eligible 
patients had 1) no cardiac disease confirmed in the cardiac evaluation, and 2) reports of either 
at least “weekly” symptoms, at least “some” effects on family life, social life, or work, or at 
least “rare but sometimes” avoidance of physical activity because of worries about the heart 
(NB different definition/level of complaints than clinically significant complaints). Ninety-
four patients meet the inclusion criteria, and of these 41 (44 %) wanted to participate in the 
treatment trial. One was excluded because he was seriously ill and died short time thereafter, 
so 40 patients were included. These patients were randomized to intervention (N=21) and 
control group (N=19). 
 
There were no significant differences between the intervention and control groups with 
regard to demographic and clinical data at the time of cardiac evaluation or  at the start of 
treatment (six-month follow-up). The prevalence of PD and any psychiatric disorder (at the 
cardiac evaluation) for the intervention and control group was 19% vs 36% and 57% vs 42%, 
respectively. 
 
Participation in the treatment trial and follow-up are summarized in Figure 3. 
Randomised
n=40
Intervention
n=21
Control
n=19
3 months 
follow-up
n=21
3 months
follow-up
n=17
12 months 
follow-up
n=20
12 months
follow-up
n=18
End of
treatment
n=18
End of 
treatment
n=21
Clinical 
significant 
complaints
n=60
Did not want
N=97
Excluded
N=1
Not fulf illed
criteria for
Clinical 
significant 
complaints
n=78
N=24
N=4
N=36
N=74
 
 
 
Figure 3 Participation in the treatment trial 
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3.2.1. Design 
Participants were randomly assigned to intervention or control groups by a web 
module, which offers block randomization. The procedure was performed by the Unit for 
Applied Clinical Research, NTNU, Norway, which is separate from the intervention location. 
Patients assigned to the control group received treatment as usual from their general 
practitioner, and were free to use the health care system when needed. As a reward for each 
set of questionnaires being returned by mail, the patients received lottery tickets worth about 
ten Euros. 
All patients were assessed at baseline (six months after the cardiological examination), 
at the end of the intervention and at three- and 12-month after the end of intervention. All 
assessments were self-report. All assessments in the control group, and the follow-up 
assessments for the intervention group, were sent to the patients by mail. 
 
 
3.2.2. Primary and secondary outcome measures 
We decided fear of bodily sensations (BSQ) to be the primary outcome measure. 
Avoidance of physical activity because of worry about the heart, symptoms of depression 
(BDI), symptom frequency, impact of the symptoms on the domains of family, social, and 
work, and HRQOL were secondary measures.  
 
 
Physical assessments during the physical exposure  
For assessment of perceived exertion, the  experienced strain during physical activity,  
the Borg scale (Borg, 1970) was used. It is scored on a 6 – 20 scale, where 6 indicates very 
light and 20 maximally strenuous exercise. This registration was done to secure the intensity 
of the exposure. In addition, registration of heart rate was done using a pulse monitor (DK 
City Fitness Polar 5261).  
 
 
3.2.3. Therapists 
All patients received individualised CBT. All patient treatments, except for two, were 
conducted by the first author (EJ), who is an experienced psychiatrist with formal training in 
CBT as a therapist and is a licensed CBT supervisor. The remaining two patients were treated 
by a physician with training in CBT, under the supervision of the first author.  
 
 
3.2.4. The treatment 
The treatment took place at the Psychiatric Outpatient Clinic at Molde Hospital, at the 
same hospital as the cardiac evaluation was performed. A treatment manual for three sessions 
of CBT was developed by the first author in cooperation with his co-authors.  There is no 
consensus in the literature about what is the optimal volume of treatment for these conditions, 
and previous studies have reported number of sessions ranging from 1 to 18. We wanted to 
develop a program which was extensive enough to cover what we thought were important 
elements in treatment, and short enough to be useful in a general clinical setting. Three 
sessions were chosen because this model would give the therapist the opportunity to 1) 
discuss the patients´ experiences obtained between the sessions and 2) revise, if necessary, 
their achieved knowledge about their symptoms 3) include a within-session exercise session. 
Each session lasted 60–90 minutes.  
In the first session the results of the previous cardiac evaluation were reviewed in 
detail, and information about heart diseases, such as coronary heart disease and arrhythmias, 
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was provided. (Figures of the heart, the coronary arteries, and the electrical impulses which 
cause heart beats were outlined on a flip-over.) We thought that medical knowledge could be 
a quick way to achieve safety regarding the heart. If one lacks knowledge, mysterious 
interpretations might erupt. Subsequently, we focussed on the physical symptoms and how 
these were interpreted by the patients. If the patients´ interpretations were catastrophic or 
inappropriate, we helped them, by means of discussion, to find alternative interpretations. For 
those who had panic disorder (n = 4), the cognitive model of panic was explained (the panic 
circle). From the start of the treatment, it was emphasized that the therapists considered the 
patients’ complaints to be real and bothersome, but that this did not necessarily prove that 
they were caused by a serious somatic illness. 
In the second session, the patients were exposed to physical activity (up to about 75% 
of maximal pulse rate) on a treadmill (DK City Fitness Polar 5261) for 12 minutes. During the 
activity, the patients were asked every second minute to rate their perceived exertion on the 
6–20 Borg scale, assess discomfort and worry on a 0–10 scale, and to verbalize all frightening 
thoughts that emerged. The aim of the session was to give each patient the opportunity to 
challenge their supposed main worry, whether they could they trust their heart or not. We 
thought the best way of challenge this fear was to expose them to physical activity in safe and 
controlled environment. On the treadmill they experienced that physical activity was tolerated 
and did not harm their hearts.  
In the third session, attention was paid to avoidance behaviours and patients’ 
interpretations of their symptoms. Avoidance behaviours, which are maladaptive behaviours 
to cope with fear, are important to discover and challenge. This is a general principle in 
treatment of anxiety disorders, and we supposed this was essential among our patients as well. 
Those who were still anxious about physical activity (avoided physical activity), were given 
the opportunity to use the treadmill to repeat the exposure. Two patients wanted to use this 
opportunity. 
To gain experience and to maintain what was achieved, all patients were encouraged 
to engage in physical activity between the sessions. 
 
 
Reporting of the treatment trial 
The treatment trial in this thesis is reported according to the CONSORT statement 
(Boutron, Moher, Altman et al. 2008). 
 
 
3.3.0. Statistical analyses 
Data were compared between groups using a chi-squared or Fisher’s exact test for 
dichotomous data, the Mann–Whitney for ordinal variables, and Student’s t-test for 
continuous variables. Multiple linear regression analysis was used to control for age and sex 
when comparing patients with chest pain and those with palpitations. The paired-samples t-
test was used to compare results for continuous variables at attendance and at follow-up. 
Correlations were calculated as Pearson’s r (for pairs of continuous variables), point-biserial 
(for one dichotomous and one continuous variable), and phi (for two dichotomous variables). 
Prediction of poor outcome (clinically significant complaints) was analysed using logistic 
regression. Analyses of covariance (ANCOVAs), using the baseline score of the dependent 
variable as a linear covariate, were used to test the differences between the intervention and 
control groups in the amount of change on outcome measures. The variance attributable to the 
intervention was assessed by partial eta squared for the intervention variable. Differences in 
the effect of treatment between the chest pain and palpitations groups, and between genders, 
were examined using ANCOVAs with multiplicative interaction terms between treatment and 
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diagnosis/gender variables (one pair at a time). Analyses testing the role of BSQ as mediator 
were performed by ANCOVAs, using the intervention/control variable as the factor, and the 
difference between baseline and three-month follow-up scores for the assumed mediator 
(BSQ) as a covariate (in addition to the baseline for the dependent variables). All tests were 
two-tailed. The alpha level was p < 0.05. The Statistical Package for Social Science (SPSS) 
version 15 or 16 software was used in all analyses. 
 
 
3.4.0. Ethical aspects 
The research protocol was accepted by the Regional Committee for Medical Research 
Ethics in Trondheim in May 2006 and by the Norwegian Social Science Data Service in 
Bergen in June 2006. Participation was voluntary and the patient’s decision to participate was 
based on written information. The patients were stimulated to contact the investigator for 
further information. It was emphasised that the decision to participate or not would not 
influence on the treatment at the outpatient clinic. One potential adverse effect of the study 
may be that the patients were asked personal questions both during the diagnostic interview 
and by the self-rating questionnaires. Exposure to such questions may be a stressful 
experience. However, no patients complained of these questions and the extensive research 
battery. Many patients expressed gratitude for the opportunity to discuss psychological/stress 
issues that they felt might be the reason why they experienced chest pain or palpitations. This 
is in accordance with the distress reduction during SCID interview found in a study of 
Scarvalone et al. (Scarvalone, Cloitre, Spielman et al. 1996).One  question is if the treatment 
group and the control group were offered equipoise treatments according to the knowledge 
before the trial. The opinion of the authors is that even if there were indications of 
effectiveness of CBT interventions, we introduced exposure to physical activity, used only 
three consultations and had a long follow-up period after the treatment, which together makes 
it acceptable to compare with treatment as usual.  
 
 
The study was registered in the ClinicalTrial.gov with ID NCT00623454 
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Summary of individual papers 
 
Paper I 
Cardiac and psychiatric diagnoses among patients referred for chest pain and 
palpitations  
Scand Cardiovasc J 2009 Aug;43(4):256-9. 
The purpose of this study was to assess the prevalence of cardiac and psychiatric diagnoses in 
patients with chest pain and palpitations. Consecutive patient (N=198), aged between 18 and 
65, referred to a cardiac outpatient unit for evaluation for chest pain or palpitations, were 
asked to participate. Patients with a previous history of heart disease, confirmed by a 
cardiologist, were excluded. The final sample comprised 160 patients. The psychiatric 
evaluation consisted of a diagnostic interview (SCID) and self-report questionnaires. The 
cardiac evaluation comprised a bicycle stress test or Holter monitoring. 
The prevalence of coronary heart disease was 4%. No cases of arrhythmia in need of 
treatment were detected. The prevalence of psychiatric disorders, among those without 
coronary heart disease, was 39%: 14% panic disorder, 14% somatoform disorders, 5% major 
depression, 20% simple phobia and 3% any current substance abuse.  
 
 
 
Paper II 
Patients with noncardiac chest pain and benign palpitations referred for cardiac 
outpatient investigation: 6-month follow-up  
Gen Hosp Psychiatry. 2010 Jul-Aug; 32(4):406-12. 
The purposes of this study were to: (1) describe the clinical status prior to cardiac evaluation 
and at six-month follow-up for patients with non-cardiac chest pain and benign palpitations; 
(2) compare the psychological characteristics of patients with non-cardiac chest pain and 
benign palpitations; (3) identify factors that might predict poor outcome and evaluate their 
suitability for screening, and to (4) identify factors associated with the patients’ interest in 
psychological treatment. The final sample at attendance comprised 154 patients, and 138 
(90%) participated at follow-up.  
At the six-month follow-up, 43% still had clinically significant complaints. Patients with 
palpitations were more likely to be female, younger, and less likely to attribute cardiac 
symptoms to heart disease, but had otherwise similar psychological features to non-cardiac 
chest pain patients. BDI depression score (five or above) at attendance predicted clinically 
significant complaints at follow-up, with sensitivity of 64% and specificity of 74%, or a 
positive predictive value of 66%. Interest in psychological treatment was associated with 
more fear of bodily sensations, more impaired function, and greater tendency to attribute 
symptoms to heart disease. 
 
 
 
 
Paper III 
Short-term cognitive behavioural therapy for non-cardiac chest pain and benign 
palpitations. A randomized controlled trial. 
Journal of Psychosomatic Research. In press. 
The aim of this study was to compare a three-session manualized cognitive behavioural 
therapy (CBT) intervention with treatment as usual for patients with non-cardiac chest pain or 
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benign palpitations in a randomized controlled trial. In addition, we wanted to evaluate 
whether change in scores of Body Sensations Questionnaire mediated changes in depression 
and avoidance of physical activity scores. 
Among eligible patients 40 agreed to participate, and these were randomly assigned to either 
an intervention (n=21) or control group (n=19). Patients in the intervention group received 
three manualized sessions with CBT, including one physical activity exposure session. The 
control group received usual care from their general practitioner. All patients completed the 
intervention. The dropouts in the intervention and control group at three and 12 month follow-
up were 0/21 vs 2/19 and 1/21 vs 1/19, respectively.   
There were significantly larger improvements in the treatment group regarding fear of bodily 
sensations, avoidance of physical activity, depression and some domains of HRQOL during 
treatment, and at three- and 12-month follow-up. A substantial proportion (about three-
quarters) of the intervention effects on depression and avoidance of physical activity could be 
attributed to (was mediated by) the reduction in fear of bodily sensations. 
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Discussion 
 
Results 
5.1.0. Summary of main results 
The prevalence of coronary heart disease among patients referred for chest pain or 
palpitations was six of 160 patients (4%). No cases of arrhythmia in need of treatment were 
detected. 
The prevalence of psychiatric disorders, among the 154 patients without coronary 
heart disease, was 39%; 14% panic disorder, 14% somatoform disorders, 5% major 
depression, 20% specific phobias and 3% any current substance abuse. The majority believed 
that it was more likely that their symptoms were caused by distress or anxiety than by a 
cardiac condition. At the six-month follow-up, 43% still had clinically significant complaints. 
Patients with palpitations were more likely to be female, younger, and less likely to attribute 
cardiac symptoms to heart disease, but had otherwise similar psychological features to those 
with non-cardiac chest pain. BDI score at attendance with cut off at five or more was a rather 
good predictor of clinically significant complaints at follow-up (sensitivity 64%, specificity 
74%, positive predictive value 66%, OR= 5.2). Among patients with clinically significant 
complaints at follow-up, 60% (36/60) were interested in psychological treatment. These had 
more fear of bodily sensations, more impaired function, and greater tendency to attribute 
symptoms to heart disease than patients not interested in psychosocial treatment. Three 
sessions of CBT, including exposure to physical activity, had significant effect on fear of 
bodily symptoms, depression, avoidance of physical activity because of worry about the heart, 
and health-related quality of life at three- and 12-month follow-up. Reduction in fear of bodily 
sensations mediated most of the change in avoidance of physical activity and depression. 
 
 
5.1.1. Discussion of the main results 
Prevalence of cardiac disorders 
The prevalence of cardiac disorders (4%) in this study was surprisingly low. Previous 
studies (Dammen  et al. 1999; Mayou et al. 1994 &1999) have also reported low prevalence 
of cardiac disorders among these patients (16 %- 34%), however, none as low as in the 
present study. This decline of the prevalence might be a result of the change in hospitalization 
policy during the past decade for patients with acute coronary symptoms. 
 
 
Prevalence of psychiatric disorders 
The prevalence of panic disorder (PD) in the present study (14%) was in line with 
another recent study (White et al. 2008), but lower than studies carried out about ten years ago 
(Dammen et al. 1999; Barsky et al 1994), where the prevalence was at least 25%. This change 
might reflect the change in hospitalization policy during the past decade, where more patients 
with acute symptoms are hospitalized. Another explanation for lower prevalence of PD today 
might be that the GPs are more aware of physical symptoms of PD and therefore send these 
patients to psychological treatment.   
The prevalence of any psychiatric disorder (39%) is still high. One explanation for the 
high prevalence of mental disorders among patients with non-cardiac chest pain and 
palpitations, especially anxiety disorders, is that in these disorders dysfunctional thinking is a 
prominent feature, and this may predispose for misinterpretations of body sensations. This 
may increase the probability that low intensity symptoms, ignored by the majority, may 
develop into bothersome and worrying complaints. This is in line with the model developed 
by Mayou (1998) where catastrophic interpretation of bodily symptoms is the key element in 
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a cognitive model explaining how the symptoms are maintained. An alternative explanation is 
that mental problems develop secondarily to the bodily complaints.  
The low prevalence of any current substance abuse fits well with the study of Dammen 
et al. (1999). One way to explain this is that you are less likely  to treat your complaints with 
drug or alcohol if you think you have  heart problem, compared to when dealing with  anxiety 
problem.  
 
 
Treatment of PD among patients with non-cardiac chest pain and benign palpitations 
In the present study only 14% of patients with PD had received adequate treatment for 
their anxiety disorder. Despite low proportion this is higher than in previous studies in cardiac 
units, where only 4% had their PD detected before and 2% during the cardiac evaluation 
(Dammen et al. 1999; Fleet et al. 1996). Even when the PD was diagnosed at the cardiac unit, 
and the patients were informed that PD could be associated with chest pain, only 22% 
received any treatment during the next year (Dammen, Bringager, Arnesen et al. 2006). Since 
effective treatment for PD is available (CBT and/or antidepressants), and the prognosis 
without adequate treatment for a significant proportion is poor, it is an obvious challenge to 
offer treatment to more of these patients. For patients referred for palpitations, we do not 
know any study which has evaluated the detection and treatment of the psychiatric disorders. 
However, based on long-term course for these patients (Mayou et al. 1999; Weber & Kapoor 
1996; Barsky, Cleary, Coeytaux & Ruskin 1995) and the similarities with those referred for 
chest pain, it is likely to suppose that PD often remains undetected among these patients as 
well.  
 
 
The natural six-month course for non-cardiac chest pain and benign palpitations 
The present study confirms the results of previous studies which report mental distress 
and sustained complaints for a significant proportion of patients referred for chest pain or 
palpitations to cardiac units and where no cardiac disorder is detected (Bringager et al. 2008; 
Potts et al 1995; Mayou et al.94 & 99). Mean score on BSQ increased during the six months 
following the cardiac evaluation. Fifty-two percent of the patients had higher score at follow-
up, 40% had lower, and 8 % had similar score when comparing follow-up with attendance. A 
normal cardiac test seems to leave the patients with anxiety about the heart, as is in 
accordance with the results from the study by Mc Donald et al. (1996). This anxiety reinforces 
the focus on the heart, which leads to increased possibility for detecting and being aware of 
functional symptoms and misinterpreting these, with development of increasingly problematic 
non-cardiac chest pain and/or benign palpitations as a consequence. The increased level of 
depressive symptoms from attendance to six-month follow-up may be a demoralisation 
reaction, due to the limitations from the somatic complaints. 
 
 
Similarities and differences between patients with chest pain and palpitations  
Patients with non-cardiac chest pain and patients with benign palpitations had similar 
prevalence of psychiatric disorders at attendance, similar level of mental distress at attendance 
and at follow-up. There was overlap of symptoms between the groups, and they did not differ 
with regard to the effects of treatment. Both in the present study as well as in the Mayou study 
(1994), those referred for palpitations were younger and more likely to be female. These 
findings of clinical characteristics support and expand the previous knowledge about the 
similarities of these two groups (Mayou et al. 1994). Therefore, with regard to psychological 
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characteristics, tendency for poor outcome, and improvement following CBT, these two 
groups could be considered as one group 
 
 
Prediction of poor outcome 
Poor outcome, defined as clinically significant complaints at six-month follow-up, was 
predicted by BDI score above five, which is below clinical cut-off (BDI>9, Klimes et al. 
1990). The BDI score correlated more strongly with clinically significant complaints than did 
the BSQ score. Because non-cardiac chest pain and benign palpitations are more closely 
associated with anxiety disorders than with depression, these results are somewhat surprising. 
This is, however, in line with a recent study where depression at baseline was a predictor for 
somatoform disorder eleven years after (Leiknes, Finset, Moum & Sandanger 2008). The 
usefulness of BDI as a screening instrument should be evaluated in new studies.    
 
 
   
Interest in psychological treatment 
Among patients with clinically significant complaints at six-month follow-up, 60% 
agreed to participate in the trial consisting of psychological treatment for their complaints. 
This result is in line with what Kisely et al. (2010) reported in the Cochrane review. 
Furthermore, the present study is the first to state that interest in psychological treatment was 
associated with fear of bodily sensations and that those patients, who were interested in 
treatment, were more likely to attribute their symptoms to heart disease. In addition, we have 
confirmed the finding from Van Peski-Oosterbaan et al. (1998), who reported that interest in 
psychological treatment was associated with limitations in activity, but not with frequency of 
symptoms.  It seems like fear of bodily symptom is a motivator for treatment and that 
changing fear of bodily symptoms is a sensible aim for the treatment. 
 
 
 
Effect of treatment for non-cardiac chest pain and benign palpitations 
The present study is the first CBT study which has included exposure to physical 
activity and assessed the patients 12 months after the end of the intervention.   
Three sessions of CBT included exposure to physical activity, was effective treatment for 
non-cardiac chest pain and benign palpitations regarding BSQ, BDI, avoidance of physical 
activity because of worry about the heart, and for HRQOL (SF-36). Esler et al. (2003) 
reported that one session with CBT was effective in reducing chest pain, but had no effects on 
HRQOL (SF-36). Sanders et al. (1997) reported that one session with information by a nurse 
(CBT) affected neither symptoms nor quality of life. Three CBT studies with up to 12 
individual sessions (Klimes et al. 1990; Mayou et al. 1997; van Peski-Oosterbaan et al. 1999) 
and one study with six group sessions (Potts et al. 1999) all reported, at least at one follow-up, 
significant reduction of chest pain and some reduction in functional impairment. Among the 
studies using non-cognitive interventions, some effect on symptoms is reported following 
hyperventilation control (DeGuire et al. 1996), hypnotherapy (Jones et al. 2006), functional 
relaxation (Lahmann et al. 2008), Johrei (Gasiorowska et al. 2008), and autogenic training 
(Asbury et al. 2009), and  some effect on functional impairment is reported following physical 
training/relaxation (Tyni-Lenne et al. 2002) and hypnotherapy (Jones et al. 2006).  
 
In general it seems like one session intervention might give some effect on symptoms 
(Esler et al. 2003; Sanders et al. 1997). However, to affect on more general well being, more 
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sessions (about ten individual sessions or 6 two-hour sessions in group) are needed (Mayou et 
al. 1997; Klimes et al. 1990; Potts et al. 1999). Our hypothesis was that exposure to physical 
activity would have such a strong impact that we could reach the aims of better general well 
being with only three sessions. Our results at three months follow-up, show obvious effect of 
the intervention on general well being (significant for 4/8 domains of SF-36) as well as on 
fear of bodily symptoms, avoidance of physical activity because of worry about the heart, and 
depressive symptoms. At 12 month follow-up the effect was still obvious for fear of bodily 
symptoms, avoidance of physical activity because of worry about the heart, and depressive 
symptoms, but the effect of HRQOL, even though a significant difference was found (1/8 
domains), was reduced. 
When we developed the treatment manual, we assumed that avoidance of physical 
activity because of worry about the heart was an essential element in sustained complaints of 
non-cardiac chest pain or benign palpitations. Therefore we included exposure to physical 
activity (waking/running on a treadmill) in the treatment. The assumption about avoidance of 
physical activity was later confirmed as 70% of those, who participated in the treatment trial, 
had at least “rare but sometimes” avoidance of physical activity because of worry about the 
heart. None of the previous treatment trials using CBT to treat non-cardiac chest pain or 
benign palpitations have included exposure to physical activity in their manuals. We suppose, 
based on feed back from the patients and clinical impression, that this exposure was critical 
for the generalized effect achieved after only three sessions.  
However, regarding the obvious effect on the more generalized measures in the 
present study, the lack of effect on symptom frequency is surprising. The questionnaire for 
measuring symptom frequency is coarse grained and time dependent, and therefore not very 
sensitive to change during the actual follow-up period. This might be an explanation for the 
lack of effect on this variable. However, our results indicate that the effects of the intervention 
were a consequence of change in the interpretation of symptoms rather than changes in 
frequency of symptoms.  
 
 
Effect sizes 
The effect sizes (partial eta Square) for BSQ, BDI and avoidance of physical activity 
are given in Table 2. The partial eta square for BSQ, BDI, and avoidance of physical activity 
at twelve month follow-up were 0.19, 0.15,and 0.19 respectively, showing that the 
intervention gave a large effect one year after the treatment (partial eta square: 0.01 is 
categorized as small, 0.06 as moderate, and 0.14 as large effect). The stable effect indicates 
that permanent changes have occurred. The measuring of effect size is important, because it 
makes it easier to compare effects of different treatments used in different trials.  
Because of differences in assessment methods and follow-up time, and lack of 
analyses of effect sizes, it is difficult to compare the effects of the present treatment study 
with the previous studies. Three of the previous CBT studies have used BDI (Mayou et al. 
2002, Klimes et al. 1990, Sanders et al. 1997), and one of these (Klimes et al. 1990) reported 
statistically significant differences between intervention and control group. However, no 
standard deviation was reported and consequently, no effect size can be calculated. None of 
the CBT studies used BSQ as outcome measure. 
 
 
Mediation of treatment effect 
Mayou (1998) have made a descriptive model for development of functional 
symptoms: They state that physiological or minor pathological symptoms are misinterpreted 
as evidence of serous illness. Once established, secondary anxiety may worsen the physical 
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symptoms. This model fits well with the cognitive model of panic and health anxiety and 
clinical experience from a wide range of functional symptoms (Mayou 1998; Mayou, Bass & 
Sharp 1995). This has, however, not previously been evaluated for patients with non-cardiac 
chest pain or benign palpitations. We wanted to test this model by analysing how much of the 
effect size of BDI and avoidance of physical activity because of worry about the heart 
(frequency of symptoms did not differ between treatment and control and could therefore not 
be included in the analysis) that could be explained by the change in BSQ. Since about 70-
75% of the effect size could be related to the change in BSQ, we consider this partly being a 
confirmation of the model. This indicates that BSQ is an important focus for treatment of 
these patients, and psychological treatment and general information to the patients during a 
normal cardiac evaluation should emphasize to reduce fear of bodily sensations. The role of 
interpretations/catastrophizing of symptoms is in line with theories about pain treatment in 
general (Quartana et al. 2009) and with treatment of chronic back pain (Smeets et al. 2006).   
 
 
   
 
 
 
Methodological issues 
5.2.0. Sample 
The sample size in paper II (N=154) is larger than in the only previous study (Mayou 
et al. 1994), which has evaluated and compared patients with non-cardiac chest pain and 
benign palpitations (N=51).  
The adherence among eligible patients was high at attendance 160/198(81%) as well as at 
follow-up 138/154 (90%). The number, who had a cardiac disorder at the cardiac evaluation 
(6/160), was too small to make statistical comparisons with those without a cardiac condition. 
Because of the small sample size, they were also excluded from the follow-up study.  
 
 
Power analyses for RCT 
It is a methodologically weak point that no power analysis and determination of 
sample size were carried out. Forty patients participated in the treatment study, 21 in the 
intervention group and 19 in the control group (paper 3). We considered the size of the groups 
to be close to the lower limit to point out significantly differences between the groups. 
However, since as much as about 95% participated in the follow-up assessments, the sample 
proved to be sufficient for statistical analyses.  
 
  
5.2.1. Internal validity 
Selection bias and confounding might reduce the internal validity. 
 
Selection bias 
We intended to study all patients fulfilling the inclusion criteria. The head of the 
cardiac outpatient clinic at Molde Hospital screened all referrals according to the inclusion 
criteria. A control procedure, ensuring that all eligible patients actually were traced for study 
participation, was not applied. Registration procedures and questions concerning the inclusion 
criteria were discussed with the investigator during the inclusion period. We have not been 
aware of any systematic bias in registration that could affect outcome. Because we did not 
control whether all eligible patients actually were registered for study referral, it is possible 
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that some eligible patients may have been missed or overlooked for study inclusion. We stated 
clearly to the head of the cardiac outpatient clinic that both patients with and without 
suspected heart disorders were eligible for study inclusion. The patients were accepted for the 
study before cardiac evaluations were made. Hence, the head of the cardiac outpatient clinic 
was blinded to the cardiac results to minimize a selection bias toward skewing of the sample 
in the direction of including patients without heart disorders. A bias may also occur if the 
phenomena of interest are associated with “unwillingness” to participate. Among the eligible 
patients, those who did not want to participate at attendance (about 19%) did not differ from 
the participants regarding prevalence of heart disorders, or other relevant variables (paper 1).  
We consider the response rate (81%) to be satisfactory and the participants to be fairly 
representative of the current target population of patients.  
At follow-up it is of interest to know whether a systematic subject loss has occurred. 
Theoretically one might assume that patients with more somatic symptoms, more worry about 
the health would be more interested in the follow-up investigations. Additionally, fully 
employed patients who are feeling well might not be willing to spend time going through a 
relatively time-consuming self-reporting exercise. The finding of more symptoms of 
depression, higher fear of bodily symptoms, and lower score for general health (SF-36) at 
follow-up compared with at attendance, raises the question whether there was such a bias. To 
evaluate a potential systematic bias, we compared the participants to the non-participants at 
follow-up regarding baseline data. No significant differences were found (paper II). Therefore 
we consider the participants at follow-up to be representative of the sample at attendance.  
 
 
Sample participating in the treatment trial 
Recruitment to the treatment trial was done by asking all patients the following 
question by mail: Do you want to participate in a research project in which we aim to explore 
the efficacy of a treatment regimen comprising three individual sessions, which has been 
developed to increase your ability to cope with chest pain and/or palpitations? The letter was, 
in addition to the person responsible for the study (EJ), signed by the head of the cardiac 
outpatient clinic. 
It is likely that more patients will accept treatment for non-cardiac chest pain or benign 
palpitations if the treatment is performed in a cardiac setting. In the present study the 
treatment was performed by a psychiatrist and physician with training in CBT in a psychiatric 
setting. However, all patients had met the first author during the psychiatric interview before 
the cardiac evaluation, and it was stated that the study was in cooperation with the cardiac 
unit. Since the proportion of participants among those with clinically significant complaints, 
is similar to that found in previous studies (40-60%) ( Kisely et al. 2010), and that they seems 
to have common characteristics as the patients in the study by Van Peski-Oosterbaan et al. 
(1998),  we consider the sample to be representative of patients who want to participate in 
such treatment.  
 
 
Confounding (internal validity) 
In paper II we used logistic regression to determine predictors of poor outcome. In this 
setting confounding will occur when the effect of a predictor is due to a common underlying 
cause which has not been identified. In this study BDI at attendance stands out as a strong 
predictor of poor outcome. Including sex and age as covariates in the analyses did no 
influence the results (these were not confounders). Potential confounders might have been 1) 
dispositional optimism/pessimism which is found to correlate with depression as well as with 
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general physical and psychological well-being (Conversano, Rotondo, Lensi et al. 2010) or 2) 
the degree of symptoms at attendance. 
 
 
5.2.2. Internal validity of the treatment trial 
Selection bias refers to the problem that at pre-test, differences between intervention 
and control group exist, and that these differences might affect the independent variable and 
thus be responsible for the observed outcome.  
The present study is a RCT. The most important advantage of proper randomization is that it 
should both eliminate selection bias and obtain balancing both with respect to known and 
unknown prognostic factors (third variables) in the assignment of treatments. In the present 
study randomization was performed by a web module which is separate from the intervention 
location. In addition, the intervention and control groups were compared regarding baseline 
data. The groups did not differ significantly for any of the variables. However, some 
differences were present. The prevalence of PD was higher in the control group 36% vs 19%, 
however, for any psychiatric disorder the prevalence was higher in the treatment group 57% 
vs 42% (Paper 3). It is unclear whether these differences may have influenced our results. 
In the present study the control group received treatment as usual, which in most cases 
involves no direct treatment of chest pain or palpitations. The patients in the intervention 
group, in addition to having three sessions with CBT, also received more care than patients in 
the control group (attention affect). The additional effect of this unspecific variable is difficult 
to measure. However, the lack of an effect of the intervention on the frequency of symptoms 
indicates that the effect of such an unspecified variable perhaps is rather negligible.  
 
 
 
5.2.3. Psychiatric assessments 
Diagnoses 
Psychiatric disorders were obtained by the SCID interview for Axis I disorders which 
is known to yield highly reliable diagnoses (Segal, Hersen & Van Hasselt 1994). It is often 
considered to be the gold standard of diagnostic assessments in clinical research. All 
interviews were performed by an experienced psychiatrist (EJ), who was trained in the use of 
the instrument. The first 15 interviews were discussed in detail with the main supervisor 
(EWM) and consensus was obtained. Ideally a selection of the interviews should be 
independently assessed by another researcher, to assess interrater reliability, but this was not 
done. All interviews were performed before the cardiac evaluation, so that the interviewer was 
blind to the results of the cardiac evaluations.  
Wulsin et al. (Wulsin, Arnold & Hillard 1991) found instability of specific anxiety and 
mood disorders when they compared attendance to 5-12 months follow up in a study 
conducted on patients with atypical chest pain presenting to an emergency room. It was noted 
that these results might be due to the difficulty in making diagnoses in medically ill patients. 
We think that this potential problem is less at an outpatient clinic, where the conditions are 
less acute, and the surroundings probably are more relaxed. However, these potential 
weaknesses in making psychiatric diagnoses in medical settings should not be disregarded.         
 
 
Self-report questionnaires 
We used questionnaires with sound psychometric properties, which are widely used 
clinically and in research, and with authorized translations (BDI, BSQ, MI, SF-36).  
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The questionnaires were filled in a relaxed atmosphere, and the interviewer was available for 
answering questions about the forms.     
In addition we developed, for follow-up, questionnaires about symptom frequency, impact of 
symptoms on family life, social life or at work, and avoidance of physical activity because of 
fear about the heart. These questionnaires are easy to understand, but not validated. There 
might have been some recall problems regarding the frequency of the symptoms, but since the 
subject probably was of interest for the patients, we think that the recall was not too bad about 
this. 
For the treatment trial we intended to use assessments which are sensitive to change in 
misinterpretations about body sensations (BSQ), impact of symptoms (scale made for the 
present study) avoidance of physical activity because of worry about the heart (scale made for 
the present study), and health related quality of life (SF-36) and depression (BDI). We found 
these assessments suitable for the purpose of the present study. However, the self-made 
questionnaire about frequency and impact of the symptoms might have been difficult to 
differentiate between the response categories.  
 
 
 
5.2.4. Cardiological assessments 
Diagnostic assessments  
The cardiac evaluation is described in the method section. All patients referred for 
chest pain underwent a bicycle stress test as a part of the cardiac evaluation. When the 
evaluations were non-conclusive, patients were sent for addition myocardial scintigraphy 
and/or coronary angiography (paper 1).   
For patients with chest pain the estimated sensitivity and specificity of the exercise ECG are 
50% and 90% respectively (Gibbons, Balady, Beasley et al. 1997). Therefore there might 
have been some patients with CAD who were not detected during the cardiac evaluation (false 
negative). 
A clinical review of exercise thallium scintigraphy reports the average sensitivity and 
specificity for the angiographic diagnoses of CAD to be 84% and 87%, respectively (Kotler & 
Diamond 1990).   
In the present study, 14 of the 16 patients who were sent for additional myocardial 
scintigraphy and 4 of the10 who were sent for additional myocardial angiography had normal 
findings. The threshold for sending patients to further investigation after the bicycle stress test 
seems not to have been too high. 
All patients except one, referred for palpitations, had a 24-hour ECG monitoring 
(Holter monitoring). If there was doubt about the conclusion from the Holter monitoring, the 
patients also underwent seven days of ECG monitoring (R-test) or a bicycle stress test. Holter 
monitoring and R-test have limitations regarding detection of intermittent arrhythmias, 
because the arrhythmias have to emerge during the recording to be detected. It is therefore 
likely that some arrhythmias were not detected. The one, who did not have a Holter 
monitoring despite referred for palpitations, had a bicycle stress test and a myocardial 
angiography. 
   
  
5.2.5. Reliability  
Inter-rater reliability is the variation in measurements when different persons use the 
same method or instruments. No inter-rater reliability analysis was performed in this study 
neither for cardiac nor psychiatric evaluations. However, the SCID-I diagnostic interviews in 
general tends to show adequate inter-rater reliability (Segal et al 1994), and in the present 
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study the 15 first interviews were discussed in detail with the main supervisor in order to 
obtain consensus. The other assessments where self-report, and assessments of interrater 
reliability is not possible.  
 
Internal consistency reliability assesses the consistency of items within a test, and is 
usually measured as Cronbach´s alpha. It  measures the average correlation between the items 
of the test. At attendance Cronbach´s alfa  for BDI was 0.90, which is satisfactory.  
 
 
5.2.6. Clinically significant complaints vs eligibility for RCT 
Using the results collected six months following the cardiac evaluation; more patients 
fulfilled the criteria as eligible for RCT in paper three than were described as having clinically 
significant complaints in paper two. The authors had the opinion that more patients than those 
defined in paper two as having clinically significant complaints, could potentially benefit 
from the treatment used in the RCT.  
 
 
5.2.7. External validity 
External validity concerns the extent to which results might be generalized to the 
target population.  
The mean scores for BDI  in this study are at the same level or somewhat lower than in 
previous studies (Mayou et al. 1994; Ehlers et al. 2000) and BSQ scores are somewhat lower 
(Dammen et al. 1999; Ehlers et al. 2000). This tendency for lower BSQ scores might be 
explained by the lower prevalence of PD, which may be due to change in referral policy, in 
which today more of the acute cases are hospitalized emergently. Therefore, in the present 
study the samples should be considered to be fairly representative of defined target 
populations of the study. The results at attendance and at six-month follow-up are therefore 
considered to be representative of patients referred for chest pain or palpitations in general. 
Further, for the treatment trial, the sample is considered to be representative and we consider 
the results valid for generalization to other patients with non-cardiac chest pain or benign 
palpitations. Whether the results of the RCT can be generalized to patients with other 
psychosomatic disorders, is unclear. 
 
 
5.2.8. Statistical analysis 
The large number of comparisons we made in the RCT raises the possibility that some 
of the significant effects were observed by chance (Type I error). On the other hand the small 
sample size in the RCT demands substantial differences between the groups in order to 
become statistically significant (danger of type II-error).  
 
 
5.2.9. Strengths and limitations 
A major strength is that the study was conducted in routine clinical practice, including 
all patients consecutively referred to a unit receiving all referrals in a catchment area, and 
with the use of methods commonly used in cardiac and psychiatric clinical practice. At 
attendance, a large proportion agreed to participate in the study and the response rate was high 
at six-month follow-up. The treatment trial has a randomized controlled design with 12-month 
follow-up. The randomization procedure was performed at a remote site of the intervention. 
The treatment was manualized and easy to apply. Most of the questionnaires used for effect 
evaluations are well known and seem to be meaningful in this setting. All patients completed 
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the treatment and a high percentage participated at follow-up. 
As for limitations, patients aged above 65 were excluded from the study. These 
comprise a rather large proportion of patients referred for cardiac evaluation and the relatively 
low frequency of patients with CAD/arrhythmias in our study may at least partly be a result of 
the exclusion of these patients. The methods used for non-invasive testing (exercise ECG, 
myocardial scintigraphy, and ECG monitoring) all have false negatives.   
The waiting time for patients referred for chest pain was two to three months, and some 
patients with psychiatric disorders and symptomatic heart disease may have recovered during 
this delay.  
Symptom attribution was assessed using two single items (mental and cardiac). 
Because symptom attribution is complex, this approach is simplistic, and important 
information might have been lost. Symptom frequency, the impact of chest pain or 
palpitations, and avoidance of physical activity because of worry about the heart were 
assessed using questionnaires developed for the present study. These instruments were not 
tested for psychometrical properties. There were some dropouts (10%) at follow-up. When 
asked about their interest in psychological treatment, patients were asked only whether they 
wanted to participate in the treatment trial or not, and we do not know the reasons for their 
decision.  
Several limitations of the treatment trial are apparent. No power analyses and 
determination of sample size were carried out. Since only about half of eligible patients 
wanted to participate, there might have been a selection bias. Those who wanted to participate 
might have been more susceptible to psychological treatment. Patients were randomized to 
CBT intervention or control condition. The patients in the control condition had less time with 
a therapist than the patients in the CBT group. The improvements observed in the intervention 
group could both be specific to the content of the treatment or could be attributed to spending 
time with a therapist alone (e.g. the placebo-attention effect). However, the finding of no 
significant changes in symptom frequency, but changes in interpretations of symptoms, 
indicate that the results are not due to an attention effect. All assessments were done by self-
report measures, and no blind rating of outcomes was included. The large number of 
comparisons we made raises the possibility that some of the significant effects were observed 
by chance. No Bonferoni correction was carried out. The small sample size, the low 
participation rate, and the limited selection of therapists restrict the generalizability of our 
findings to the general clinical setting.  
   
 
5.3.0. Suggestions for future research 
Cardiac and psychiatric diagnosis 
The prevalence of cardiac diagnoses was surprisingly low, and new studies should 
evaluate these findings. Our results might be a result of lowering of the threshold for referral 
for cardiac evaluation. Anyhow, many patients at a cardiac unit have normal test result. Little 
is known about the consequences of referring patients with few symptoms and no heart 
disease to a cardiac evaluation. It is of interest to know whether this procedure develops 
anxiety among the patients and how the normal test influence on the potential anxiety. 
Studies, which aim to find the best way to inform the patients about a normal cardiac test, are 
recommended. 
Psychiatric disorders are common among patients with non-cardiac chest pain and 
benign palpitations. Most focus has been directed to PD, since the physical symptoms are 
common during a panic attack. However, in the present study the prevalence of PD was lower 
than in previous studies. Since more acute cases today are urgently hospitalized, it is likely 
that more cases with PD are hospitalized rather than referred for outpatient evaluation. We 
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therefore suggest new studies which evaluate the prevalence of PD among patients with chest 
pain or palpitations in emergency units. 
  
 
Screening for poor outcome among patients with non-cardiac chest pain or benign 
palpitations 
Screening might be a proper way to detect patients with poor outcome. In the present 
study BDI seemed to be suitable for this purpose, and this should be evaluated in future 
studies. Further studies should also try to find/develop even simpler assessment for this 
purpose.  
 
 
Interest in psychological treatment 
Even though it seems like those who are most disabled from their symptoms are 
interested in psychological treatment, still there are patients who of unknown reasons choose 
not to participate. This should be further evaluated. 
 
 
Illness perception  
We have evaluated the association between fear of body sensations and outcome. It is 
likely that other interpretations of the symptoms might be important for outcome among 
patients with non-cardiac chest pain or benign palpitations. Identification of these 
interpretations is important because it might be important elements in newer and more 
effective treatments.  
 
 
Treatment 
Still few randomized controlled trials among patients with non-cardiac chest pain or 
benign palpitations are published. This is the first RCT with three sessions or less, which had 
an  effect on generalized measures like health related quality of life and avoidance of physical 
activity. This is also the first CBT based RCT with twelve months follow- up. Replication of 
the present study with larger samples and further research about short term and easily applied 
treatments for these patients is recommended.  
  
 
5.4.0. Implications for clinical practice 
Most patients referred for chest pain or palpitations have no heart disease. Among 
patients with non-cardiac chest pain and benign palpitations, a significant proportion have 
poor outcome. A cardiac evaluation is necessary, but a negative cardiac evaluation is not 
sufficient to solve the problems.  Since psychiatric disorders are common among these 
patients, they easily fall between two chairs. It is therefore essential that general practitioners 
and cardiologists are aware of them, make an effort to detect them and cooperate about giving 
adequate treatment. This thesis has shown that a simple self report questionnaire for 
depression at the cardiac evaluation might be a simple way of reaching the patients who are 
vulnerable to develop sustained complaints.  For those with sustained complaints six months 
after the cardiac evaluation, a standard intervention of three sessions of CBT including 
exposure to physical activity is an acceptable and effective treatment.   
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General conclusions 
Among patients referred to cardiac out patient clinic for chest pain or palpitations, only a 
minority have cardiac disorders.   
 
Psychiatric disorders are common, and especially the prevalence of panic disorder and 
somatisation disorder are high. 
 
 
Among patients with no heart disease, symptoms of depression and anxiety increased and 
general health (domain of SF-36) deteriorated during a six-month observation period 
following a normal cardiac investigation.  After six months 43% had clinically significant 
complaints.  
 
Depression score at admission predicted clinically significant complaints at six-month follow-
up. BDI score of five or above had rather good screening properties for clinically significant 
complaints at follow-up, sensitivity of 64% and specificity of 74%. 
 
Patients with benign palpitations were more likely to be female and younger, and less likely to 
attribute their symptoms to cardiac disorder, otherwise they had similar characteristics 
regarding prevalence of psychiatric disorders, psychological distress, and tendency to develop 
sustained complaints compared to those with non-cardiac chest pain.   
 
Among patients with clinically significant complaints at follow-up, 60 % were interested in 
participating in a treatment trial for evaluating short term psychological treatment (cognitive 
behavioural therapy). Those who were interested in psychological treatment to a higher 
degree attributed their symptoms to heart disorder at attendance and had more fear of bodily 
sensations and limitations in activity at follow-up. 
 
Three sessions of cognitive behavioural therapy, including exposure to physical activity, 
reduced the impact of symptoms, fear of bodily symptoms, depression, and increased health 
related quality of life. The effect lasted at least12 months after the end of treatment.  
 
Changes in interpretations of bodily sensations mediated most of the effects on depression and 
avoidance of physical activity. 
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Tables 
 
Table 1 DSM-IV criteria for panic attack and panic disorder 
 
Panic attack 
A discrete period of intense fear or discomfort, in four (or more) of the following symptoms 
develop abruptly and reached a peak within 10 minutes.  
 
(1) palpitations, pounding heart, or accelerated heart rate 
(2) sweating  
(3) trembling or shaking 
(4) sensations of shortness of  breath or smothering 
(5) feeling of choking 
(6) chest pain or discomfort 
(7) nausea or abdominal distress 
(8) feeling dizzy unsteady lightheaded, or faint 
(9) derealization (feeling of  unreality) or depersonalization (being detached from oneself) 
(10) fear of loosing control or going crazy 
(11) fear of dying 
(12) paresthesias (numbness or tingling sensation) 
(13) chills or hot flushes 
 
 
Panic Disorder 
A. Both (1) and (2): 
 
(1) Recurrent unexpected panic attacks 
(2) At least one of the attacks has been followed by one months (or more) of one (or 
more) of the following: 
(a) persistent concern about having additional attacks  
(b) worry about the implications of the attacks or its consequences (e.g. losing 
     control, having heart attack, going crazy) 
(c) a significant change in behavior related to the attacks 
 
B. Absence of agoraphobia 
C. The panic attacks are not due to the direct physiological effect of a substance (e.g. drug 
abuse, medication) or a general medical condition (e.g. hyperthyroidism) 
D. The panic attacks are not better accounted for by another mental disorder. 
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Table 2 Effect size (partial eta square) following three sessions of CBT (ANCOVA) 
 
 
Variables End of treatment Three-month  
follow-up 
Twelve-month 
follow-up 
Body sensation 
questionnaire 
0.53 0.30 0.19 
Beck Depression 
Inventory 
0.19 0.18 0.15 
Avoidance of 
physical activity 
0.15 0.21 0.19 
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Abstract
Objectives: The aims were to (a) study the characteristics and outcome in patients with noncardiac chest pain or benign palpitations referred
for cardiac evaluation, (b) compare psychological characteristics in the two groups, (c) identify predictors of outcome (d) and explore
characteristics of patients who wanted psychological treatment.
Methods: The patients (N=154) were first evaluated by a psychiatrist and than by a cardiologist at the initial attendance and by self report
after 6 months.
Results: Thirty nine percent had at least one DSM-IV psychiatric disorder at attendance. At the 6-month follow-up, 43% still had clinically
significant complaints and/or impaired function. Patients with palpitations were more likely to be female, younger and less likely to attribute
cardiac symptoms to heart disease, but had otherwise similar psychological features to noncardiac chest pain patients. Depression score at
attendance predicted significant complaints at follow-up. Interest in psychological treatment was associated with more fear of bodily
sensations, more impaired function, and greater tendency to attribute symptoms to heart disease.
Conclusion: Psychiatric disorders were common. The 6-month outcome was poor and was associated with the depression score at
attendance. Patients with fear of bodily symptoms and impaired function were most interested in psychological treatment.
© 2010 Elsevier Inc. All rights reserved.
Keywords: Chest pain; Palpitations; Follow-up; Interest in treatment
1. Background
Chest pain and palpitations are common in the general
population, with prevalence rates of 20–40% and 11%,
respectively [1–3], and are the two most common reasons for
referral to a cardiologist [4]. In cardiac settings, a
considerable proportion of these patients have no heart
disease or other medical disorder that can account for their
symptoms [5–7]. Previous studies in cardiac settings have
found a high frequency of psychiatric disorders (25–50%),
especially panic disorder (PD) [6,8,9] and reduced quality of
life [10–13] among these patients. Follow-up studies have
reported poor outcomes in terms of maintenance of
symptoms that affect daily life, worry about the heart, and
increased use of health care services. This is especially true
for patients with psychiatric disorders [14–16], who are
rarely offered any specific treatment besides the cardiac
evaluation [17,18].
During the past decade, there has been a change in referral
policy for patients with acute coronary syndrome. Most of
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these patients are now hospitalized urgently and not referred
for outpatient evaluation. Whether this new referral policy
has led to fewer cases with acute symptomatology (e.g., PD)
has not been investigated thoroughly [19]. On the other hand,
continual provision of information about the importance of
early detection of cardiac disorders might have lowered the
threshold for referrals.
Most research has focused on chest pain patients, whereas
less attention has been given to those with palpitations. The
importance of improving health care for patients with
noncardiac chest pain is well documented [15,16]. Whether
patients with palpitations have the same needs has not been
investigated thoroughly.
In both patients with noncardiac chest pain and benign
palpitations, there is some evidence of an association between
psychiatric disorders and subsequent poor outcome [14,15].
However, there is a need to identify the predictors of poor
outcomes and to explore their value for screening patients.
Cognitive behavioural therapy has been documented to
be effective in treating patients with noncardiac chest pain
and benign palpitations [20,21], but a low percentage of
eligible patients (40–60%) elect to seek such treatment. It is
of interest to enhance the understanding about the
characteristics of the patients who want to participate in
psychological treatment, in order to target them for
psychological treatment.
The aims of the present study were to:
(1) describe the clinical status prior to cardiac evaluation
and at 6-month follow-up for patients with noncardiac
chest pain and benign palpitations;
(2) compare the psychological characteristics of patients
with noncardiac chest pain and benign palpitations;
(3) identify factors that predict poor outcome and
evaluate theirs suitability for screening and
(4) identify factors associated with the patients' interest
in psychological treatment.
2. Methods
2.1. Patients
Consecutive patients referred to the cardiac outpatient
unit at the Molde Hospital in Norway between May
2006 and May 2007 for evaluation of chest pain or
palpitations were asked to participate. This outpatient
clinic receives all referrals in a catchment area of about
75,000 inhabitants.
The head of the cardiac unit screened all referrals. The
inclusion criteria were: (1) referral for a main complaint of
chest pain or palpitations; (2) age 18–65 years and (3) ability
to understand and write the Norwegian language. The
exclusion criteria were: (1) mental retardation; (2) psychosis;
or (3) organic heart disease confirmed by a cardiologist.
Among 219 consecutive patients, 21 cancelled both the
cardiac and psychiatric evaluation, and 36 did not want to
participate in the study. A total of 162 patients participated in
the psychiatric and cardiac evaluations at admission (Fig. 1).
Of these, eight were excluded, six because of coronary heart
disease confirmed by the cardiac evaluation (five in the chest
pain group and one in the palpitation group), one because of
lack of Norwegian language competency, and one because
of mental retardation. No arrhythmias in need of treatment
were detected.
In the final sample, which comprised 154 patients, 107
were referred because of chest pain and 47 because of
palpitations. The 36 patients who did not want to participate
in the study did not differ significantly from the participants
on age, sex, prevalence of heart disease (as assessed by the
cardiac evaluation), or chest pain/palpitations ratio.
2.1.1. Sample at the 6-month follow-up
Of the total sample of 154 patients, 138 (90%) responded
to mailed questionnaires at the 6-month follow-up: 95 (89%)
in the chest pain group and 43 (91%) in the palpitations
group (Fig. 1). The participants who did not participate at
follow-up did not differ from the participants who responded
on sex, age, prevalence of psychiatric disorders, or scores on
any variable with importance for the outcome (i.e.,
depression, anxiety symptoms, and avoidance).
2.1.2. Cardiac evaluation
The patients referred for chest pain underwent a standard
bicycle stress test. If the cardiologist found the results
consistent with coronary heart disease or if there was doubt
about the diagnosis, the patients were referred for myocardial
scintigraphy or coronary angiography. The patients referred
for palpitations were monitored with Holter monitoring. If
there was doubt about the conclusion from the Holter
monitoring, the patients also underwent 7 days of electro-
cardiography monitoring (R-test) or a bicycle stress test.
2.2. Assessments at attendance
Sex, age, marital status, education, work status, duration
of symptoms and days on sick leave during the three months
before the consultation were registered at attendance.
Psychiatric disorders were assessed using the Structured
Clinical Interview for DSM-IV Axis I disorders [22]. The
interviews were performed by the first author, an experi-
enced psychiatrist, who was trained in the use of the
instrument. For current diagnoses, the criteria had to be met
within one month before the interview; for lifetime
diagnoses, the criteria had to be met previously or currently.
All patients were informed about the results of the
psychiatric evaluation.
2.2.1. Depression, anxiety, and health-related quality of
life (HRQOL)
The Beck Depression Inventory (BDI) [23] measures the
level of depression. The BDI comprises 21 items that are
rated on a 0–3 scale.
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The Body Sensations Questionnaire (BSQ) [24] measures
fear of body sensations. The BSQ comprises 17 different
bodily symptoms that are rated on a 1–5 scale.
The Mobility Inventory (MI) [25] measures avoidance in
24 different places or situations and is rated on a 1–5 scale.
For each place or situation, the patients indicated when they
were alone or accompanied by others.
The 36-item SF-36 [26] measures the patient's percep-
tions of HRQOL and function across eight areas of life
(domains): physical functioning, physical role limitations
(i.e., role limitations because of physical health problems),
bodily pain, general health perception, vitality, social
function, emotional role limitations (i.e., role limitations
because of emotional problems), and mental health. Domain
scores range from 0 to 100; higher scores indicate better
health. A validated Norwegian translation of the SF-36 was
used in the present study [27,28].
These self-rating questionnaires are used widely in
clinical practice and research, and cover central aspects of
depression, anxiety, and HRQOL.
2.2.2. Symptom attribution
Patients were asked the following questions: (1) To what
degree do you find it likely that your symptoms are caused
by a heart disease? (2) To what degree do you find it likely
that your symptoms are caused by mental stress or anxiety?
The responses were categorized as: 1, not likely; 2, less
likely; 3, most likely and 4, for sure.
2.2.3. Treatment of psychiatric disorders
Psychotherapy was defined as at least one session with
psychological treatment/counselling for mental problems
during the patient's lifetime. The following current medica-
tions were registered: use of antidepressants, anxiolytics,
hypnotics, or other medications for mental disorders.
2.3. Assessment at follow-up
2.3.1. Frequency of symptoms
Symptoms of chest pain or palpitations were recorded on
a registration form developed for the present study. The
frequency of symptoms was rated as: 1, daily; 2, weekly or
more often; 3, rarely but sometimes; or 4, no symptoms in
the last 6 months. For patients who reported both chest pain
and palpitations, the highest frequency score was entered in
the statistical analyses.
2.3.2. Consequences of chest pain and palpitations
The impact of cardiac symptoms on the domains of
family, social, and work life were recorded separately as: 1,
high impact; 2, moderate impact; 3, some impact and 4, no
impact. The highest score (the domain most affected) among
the three was used.
Avoidance of physical activity was assessed using the
following question: “Do you avoid physical activity because
of worries about the heart?” The response categories were: 1,
often; 2, now and then; 3, rarely but sometimes and 4, never.
2.3.3. Clinically significant complaints at follow-up
Clinically significant complaints at follow-up were
defined as reports of at least one of the following: At least
weekly symptoms; moderate impact on family life, social
life, or work; or avoiding physical activity now and then
because of worries about the heart. Clinically significant
complaints were categorized as present or not present. The
purpose of the generation of this variable was to identify
individuals who were considered to be in need of treatment.
All patients with clinically significant complaints were
evaluated as being in need of treatment.
2.3.4. Interest in psychological treatment at follow-up
At the 6-month follow-up, all patients were asked the
following question: “Do you want to participate in a research
Fig. 1. Flow diagram of study participation.
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project in which we aim to explore the efficacy of a treatment
regimen comprising three individual sessions, which has
been developed to increase your ability to cope with chest
pain and/or palpitations?” Response categories were: 1, yes;
2, I want more information on the phone and 3, no.
2.4. Procedure
The inquiry about participation in the study was mailed
together with information about the appointment at the
cardiac outpatient clinic. The patients were informed that the
purpose of the study was to evaluate psychological distress
and prevalence of psychiatric disorders among patients
referred for chest pain or palpitations. The psychiatric
evaluation and assessments at attendance were performed
before the cardiac evaluation; thus, the interviewer and the
patients were blind to the results of the cardiac evaluation.
All information about the patients at the 6-month follow-up
was collected by mail (except for interest in treatment, for
which some patients were phoned).
2.5. Ethics
The research protocol was approved by the Regional
Committee for Medical Research Ethics in May 2006 and by
the Norwegian Social Science Data Service in June 2006. All
participating patients signed an informed consent form.
2.6. Statistical analysis
Data were compared between groups using a chi-squared
or Fisher's Exact test for dichotomous data, the Mann–
Whitney for ordinal variables, and Student's t-test for
continuous variables. Multiple linear regression analysis
was used to control for age and sex when comparing
patients with chest pain and those with palpitations. The
paired-samples t-test was used to compare results at
attendance and at follow-up. Correlations were calculated
as Pearson's r (for pairs of continuous variables), point-
biserial (for one dichotomous and one continuous variable),
and phi (for two dichotomous variables). Prediction of poor
outcome (clinical significant complaints) was analysed
using logistic regression. All tests were two-tailed. Pb.05
was considered significant. The SPSS version 16 software
was used in all analyses.
3. Results
3.1. Clinical status at attendance
3.1.1. Demographic and clinical data
The demographic and clinical are shown in Table 1. Those
referred for palpitations were younger and included more
women; otherwise the groups did not differ significantly.
3.1.2. Prevalence of psychiatric disorders
The prevalence of current psychiatric disorders and level
of mental distress are shown in Table 2. In addition to the
current diagnoses, 31 (20%) had lifetime major depression,
and 57 (31%) had any lifetime anxiety disorder. There were
no significant differences between patients with chest pain
and palpitations regarding the prevalence of psychiatric
disorders, level of depression and anxiety, or avoidance
(Table 2). Adjusting for age and sex did not change the
results (data not shown).
3.1.3. Symptom attribution
In both groups combined, 26% of patients reported “most
likely” or “for sure” that their complaints were caused by
heart disease. Most patients (64%) attributed their symptoms
(“most likely” or “for sure”) to mental distress or anxiety.
Patients with palpitations were less likely to attribute their
symptoms to heart disease. The scores for palpitations and
chest pain were “not likely,” 17% vs. 5%; “less likely,” 69%
vs. 62%; “most likely,” 12% vs. 29% and “for sure,” 2% vs.
3% (P=.014, Mann–Whitney U test). The groups did not
differ regarding the attribution of symptoms to mental stress
or anxiety.
Table 1
Demographic and clinical data at attendance
Total
N=154
Chest pain
N=107
Palpitations
N=47
P
Women 85 (55%) 51 (48%) 34 (72%) .005a
Age, median (range) 52 (18–65) 54 (18–65) 44 (21–62) b.001b
Married/cohabiting 119 (77%) 85 (79%) 34 (72%) ns
Vocational school/university 108 (70%) 75 (71%) 33 (70%) ns
Main source of income past 6 months:
Work 101 (66%) 70 (65%) 31 (66%) ns
Sickness benefit 41 (26%) 29 (27%) 12 (26%) ns
Other 12 (8%) 8 (8%) 4 (8%) ns
Duration of symptoms in months before evaluation, median (range) 9.5 (1–420) 12 (1–420) 6 (2–360) ns
Days on sick leave past 3 months median (range) 6 (0–90) 6.5 (0–90) 2.5 (0–90) ns
ns, not significant.
a chi-squared test.
b Mann–Whitney U test.
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3.1.4. Psychiatric treatment
In the combined group, 13 patients (8%) used selective
serotonin reuptake inhibitors, eight (5%) anxiolytics, 26
(17%) hypnotics and 41 (27%) had received psychotherapy
during their lifetime. Of the 22 patients with current PD,
three received antidepressants; two of these attended
psychotherapy and one was on the waiting list at a
psychiatric outpatient clinic, meaning that only 3 of 22
(14%) patients with PD received adequate treatment. Of the
seven patients with current major depression, two received
antidepressants. There were no differences between the chest
pain and palpitations groups regarding the use of psycho-
tropic medication or attendance for psychological treatment.
3.2. Status at follow-up
In both groups combined, 43% (60/138) had clinically
significant complaints, 39% (54/138) reported at least “rare
but sometimes” avoidance of physical activity because of
worry about the heart. Patients with clinically significant
complaints did not differ significantly from the remaining
regarding sex, age, reason for referral (chest pain or
palpitations), days on sick leave before attendance, or
whether they attributed their symptoms to mental or cardiac
conditions. However, they had a higher frequency of panic
disorder, depression, and any psychiatric disorder, and
longer duration of actual symptoms (median, 6 vs. 12
months; P=.03) before attendance. Patients with clinically
significant complaints also at follow-up had significantly
higher scores for BDI, BSQ, andMI, and lower quality of life
on all eight domains of HRQOL.
There was a non-significant tendency for patients referred
for palpitations to have had more frequent symptoms than
those referred for chest pain (P=.053); otherwise, the groups
did not differ significantly at follow-up.
There was some overlap of symptoms between the
groups. Among patients referred for chest pain, 20%
reported at least weekly palpitations, and among those
referred for palpitations, 14% reported at least weekly
chest pain.
3.3. Course from attendance to the 6-month follow-up
For the whole sample there was a significant increase
from attendance to follow-up in BDI (mean±S.D., 5.0±5.5
vs. 5.8±6.3; P=.04)and BSQ score (mean, 1.61±0.54 vs.
1.71±0.63; P=.04), whereas this was not the case for MI
scores. The analysis of SF-36 results revealed that, at
follow-up, the score for bodily pain was higher (better
health) (mean, 62.4±24.8 vs. 68.0±25.4; P=.007) and
general health was lower (poorer health) (72.6±18.6 vs.
68.1±20.5; P=.002).
Table 2
Prevalence of current psychiatric disorders and intensity of psychiatric
symptoms at attendance
Diagnoses Total
N (%)
Chest pain
N (%)
Palpitations
N (%)
P
Total 154 (100%) 107 (69%) 47 (31%)
Panic disorder 22 (14%) 16 (15%) 6 (13%) ns
Any anxiety disorder 48 (31%) 34 (32%) 14 (30%) ns
Major depression 7 (5%) 5 (5%) 2 (4%) ns
Any somatoform disorder 21 (14%) 14 (13%) 7 (15%) ns
Any current substance abuse 4 (3%) 4 (4%) 0 ns
Any current psychiatric disorder 60 (39%) 41 (38%) 19 (40%) ns
BDI, mean (S.D.) 4.9 (5.4) 5.1 (5.5) 4.5 (5.1) ns
BSQ, mean (S.D.) 1.6 (0.5) 1.6 (0.6) 1.6 (0.5) ns
MI, mean (S.D.) 1.2 (0.4) 1.2 (0.5) 1.2 (0.3) ns
Table 3
Patients with sustained complaints (N=60) at the 6-month follow-up
Total
(N=60)
Interested in
treatment (N=36)
Not interested in
treatment (N=24)
P
Frequency of symptoms, mean (S.D.) 2.1 (0.6) 2.0 (0.6) 2.1 (0.7) ns
Impact on family life, social life, or work, mean (S.D.) 2.8 (0.7) 2.6 (0.6) 3.2 (0.7) .001
Avoidance of physical activity because of worry about
the heart, mean (S.D.)
3.0 (1.0) 2.8 (0.9) 3.4 (0.9) .008
BDI, mean (S.D.) 8.5 (7.5) 10.0 (8.2) 6.2 (5,7) .06
BSQ, mean (S.D.) 1.8 (0.7) 2.0 (0.7) 1.5 (0.5) .005
MI, mean (S.D.) 1.4 (0.5) 1.5 (0.6) 1.3 (0.3) ns
SF-36
Physical functioning, mean (S.D.) 82.7 (16.1) 80.0 (16.4) 84.3 (17.6) ns
Role limitations; physical, mean (S.D.) 51.3 (42.1) 44.4 (42.7) 57.6 (41.6) ns
Bodily pain, mean (S.D.) 57.2 (22.9) 51.6 (19.9) 64.7 (26.1) .05
General health perception, mean (S.D.) 61.2 (20.1) 56.4 (20.5) 65.1 (22.2) ns
Vitality 44.2 (20.6) 39.7 (20.2) 52.3 (19.1) .02
Social functioning, mean (S.D.) 79.6 (23.6) 75.3 (26.6) 83.7 (23.4) ns
Role limitations; emotional, mean (S.D.) 69.0 (41.2) 63.9 (44.6) 75.4 (36.5) ns
Mental health, mean (S.D.) 72.5 (17.9) 69.9 (19.4) 77.3 (14.0) ns
Comparison of patients interested/not interested in psychological treatment.
SF-36, 36-Item Short Form Health Survey.
All were analyzed using the Mann–Whitney U test.
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3.4. Predictors of poor outcome
There were significant correlations between presence of
clinically significant complaints at follow-up and the
baseline variables BDI (r=0.37, Pb.001); BSQ (r=0.21,
P=.02); diagnosis of depression [r(phi)=0.27, P=.002]; PD
[r(phi)=0.29, P=.002]; and any psychiatric disorder [r
(phi)=0.20, P=.02]. To determine whether BDI could serve
as a screening tool for clinically significant complaints at
follow-up, the BDI score was collapsed into the dichot-
omous variable with cutoff at five or greater. This cutoff
gave the strongest correlation with clinically significant
complaints. The correlation was r(phi)=0.39 (Pb.001,
OR=5.2), corresponding to a sensitivity of 64% (38/59)
and specificity of 74% (58/78), or a positive predictive
value of 66% (38/58).
3.5. Interest in psychological treatment
At follow-up, 44/138 (32%) were interested in psycho-
logical treatment. Of these, 11 received information by
telephone before making a decision.
Among the 60 patients with clinically significant
complaints at follow-up, 36 (60%) were interested in
psychological treatment. The differences between those
interested in psychological treatment and those not interest-
ed, are shown in Table 3. Those interested in psychological
treatment to a higher degree attributed their symptoms to
heart disease, mean (S.D.) 2.3 (0.7) vs. 1.9 (0.6), P=.02.
When collapsing the variable, “To what degree do you find it
likely that your symptoms are caused by a heart disease?”
into two groups — (1) not likely/less likely and (2) most
likely/for sure — those in the latter group (most likely/for
sure) had a higher BSQ score at attendance and follow-up
[mean (S.D.), 1.52 (0.47) vs. 1.78 (0.63), P=.006 and 1.63
(0.54) vs. 1.93 (0.78) P=.04, respectively].
4. Discussion
At attendance 39% had any psychiatric disorder and 14%
had PD. The majority believed that it was more likely that
their symptoms were caused by distress or anxiety than by a
cardiac condition. At 6-month follow-up 43% had clinically
significant complaints, and this was associated with
depression scores at attendance. Patients with benign
palpitations had similar psychological characteristics as
those with noncardiac chest pain. Those who were interested
in psychological treatment, had reduced vitality, more fear of
bodily sensations and were more likely to attribute their
symptoms to heart disease.
The incidence of PD among patients with noncardiac
chest pain was lower than that in studies performed some
years ago, where the incidence was N25% [29]. The mean
BSQ score in our sample is lower than in other clinical
samples [6,8] but is higher than the scores in the general
population [24]. Because PD often presents with acute
symptoms, the lower prevalence might be explained by the
change in referral procedure over the past decade, where
more acute cases are urgently hospitalized.
Most patients attributed their symptoms to mental
distress. This indicates that many patients are aware of the
connection between physical symptoms and mental distress.
Several other studies have reported poor long-term
outcome for patients with noncardiac chest pain and benign
palpitations [14–16], and our study confirms these findings.
Almost half (43%) had clinically significant complaints
at follow-up.
Clinically significant complaints at follow-up was pre-
dicted by BDI scores, and BDI score above five seems to be a
good predictor of poor outcome. The usefulness of BDI as a
screening instrument should be evaluated in new studies.
The present study indicates that patients with benign
palpitations have the same need for treatment as those with
noncardiac chest pain. The similar fear of bodily symptoms,
as assessed by the BSQ, is of special interest. Catastrophic
interpretation of bodily symptoms is the key element in the
cognitive model explaining how the symptoms are main-
tained [4]. Our results suggest that psychological treatment
aiming to reduce fear of bodily symptoms is appropriate for
both groups.
To our knowledge, no previous studies have explicitly
investigated avoidance of physical activity because of
worries about the heart, which was frequently reported in
both groups. Avoidance of physical activity due to
catastrophic beliefs about heart disease may contribute to
the maintenance of symptoms.
Sixty percent of the patients with clinically significant
complaints at the 6-month follow-up wanted psychological
treatment, and this fits well with a previous review [20]. One
previous study [30] reported that interest in psychological
treatment was associated with limitations in activity, but not
with frequency of symptoms. In addition to confirm these
findings, the present study shows an obvious association
between interest in psychological treatment and fear of
bodily sensations. Patients who were interested in treatment
were also more likely to attribute their symptoms to heart
disease. This might be explained by the increased fear of
bodily symptoms among those who attributed their symp-
toms to heart disease.
4.1. Study strengths and limitations
A major strength is that the study was performed in a
general cardiac setting and included consecutive patients in a
catchment area. A limitation is that patients older than 65
yearswere excluded. Thewaiting time for patients referred for
chest pain was two to three months, and some patients with
psychiatric disorder may have recovered during this delay. No
non-clinical control group was included, and it is therefore
difficult to evaluate to what extent the studied sample differs
from the general population. Symptom attribution was
assessed using two single items (mental and cardiac). Because
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symptom attribution is complex, this approach is simplistic,
and important information might have been lost. The impact
of chest pain or palpitations and avoidance of physical activity
because of worry about the heart were assessed using
questionnaires developed for the present study. These
instruments were not tested for psychometrical properties.
There were some dropouts (10%) at follow-up. It is likely that
those, who were worried about their health and/or experi-
enced sustained complaints, were more interested in partic-
ipation in the follow-up investigation, and this might have led
to systematic subject loss. When asked about their interest in
psychological treatment, patients were asked only whether
they want treatment or not, and we do not know the reasons
for their decision.
5. Conclusions
Psychiatric disorders were common among patients with
noncardiac chest pain or benign palpitations. Symptoms and
psychological distress tended to persist despite the negative
cardiac evaluation, and depression score was a predictor of
outcome. Patients with noncardiac chest pain and benign
palpitations have similar psychological features. Interest in
psychological therapy was significantly associated with fear
of bodily symptoms and limitations in activity.
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